Clinical trial register · France

Clinical Trials in Villejuif, 2026

Every study on the ClinicalTrials.gov registry that lists a site in France and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV

Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 9731 matching records held by the registry are in this view. Synced 02 Nov 2026, 03:18 UTC

9731

Studies in scope

all four open statuses

6052

Recruiting now

open to new participants

1028

Lead sponsors

across recruiting studies

Top sites

Paris 2829 Lyon 1396 Bordeaux 1393 Marseille 1295 Lille 1283

Trials with a site in Villejuif

Status

Study

Lead sponsor

Phase

Enrol

Sites in France

Start

Not yet open

Doxorubicin With or Without DT-7012 in Advanced Soft Tissue Sarcoma

NCT07802652Undifferentiated Pleomorphic Sarcoma (UPS), Dedifferentiated Liposarcoma (DDLPS)

DrugsDT-7012·Doxorubicin

Gustave Roussy, Cancer Campus, Grand Paris

Phase 2

Villejuif

2027-02-01

Not yet open

Evaluation of the Efficacy and Safety of Neoadjuvant Therapy in Patients With Surgically Resectable Pancreatic Adenocarcinoma.

NCT07808567Pancreatic Adenocarcinoma Resectable, Non Metastatic, ECOG Performance Status Score of 0 or 1

DrugsFolfirinox·Nab-paclitaxel·Gemcitabine

Gustave Roussy, Cancer Campus, Grand Paris

Phase 2

Villejuif

2027-01

Not yet open

A Study to Assess the Safety and Tolerability of BMS-986527 in Participants With Clear Cell Renal Cell Carcinoma (ccRCC)

NCT07848295Clear Cell Renal Cell Carcinoma (ccRCC)

DrugsCabozantinib·Opdivo·Nivolumab

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Phase 1

112

Villejuif, Marseille

2026-12-31

Not yet open

Study Investigating the Safety of Anti-CD19 CAR-T Cells Therapy Produced at Gustave Roussy for Adults With Severe and Refractory Systemic Autoimmune Rheumatic Diseases

NCT07544225Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Sjogren's Disease With Dry Eyes, Systemic Sclerosis (SSc)

Gustave Roussy, Cancer Campus, Grand Paris

Phase 1

Villejuif

2026-12-01

Not yet open

A Study to Assess The Safety and Tolerability of Pumitamig-Based Therapy Administered Before Surgery in Participants With Early-Stage Non-Small Cell Lung Cancer (ROSETTA Lung-220)

NCT07871214Early-Stage Non-Small Cell Lung Cancer

DrugsPumitamig·Pemetrexed·Paclitaxel·Cisplatin

Bristol-Myers Squibb

Phase 2

Rennes, Villejuif, Toulouse, Paris

2026-11-30

Not yet open

Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets

NCT07234877Non Small Cell Lung Cancer

DrugsPaclitaxel-albumin·Ivonescimab·Pemetrexed·Paclitaxel

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2

158

Clermont-Ferrand, Lyon, Nice, Reims, Villejuif

2026-11

Not yet open

Best Salvage Treatment for High-risk Relapsing Prostate Cancer (PEACE-9 - ESCALATE-RT)

NCT07782112Prostatic Neoplasms, Biochemical Recurrence, Oligometastatic Prostate Cancer

DrugEnzalutamide

Ente Ospedaliero Cantonale, Bellinzona

Phase 3

140

Bordeaux, Lille, Saint-Etienne, Saint-Herblain, Villejuif

2026-11

Not yet open

DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers

NCT07707895Small Cell Lung Cancer, Large Cell Neuroendocrine Lung Carcinoma, Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology, Extrapulmonary Neuroendocrine Carcinoma of Large Cell Histology

DrugsZL-1310·Obrixtamig·Atezolizumab

Boehringer Ingelheim

Phase 1/2

Lyon, Marseille, Villejuif

2026-10-28

Recruiting

A Study to Test Different Doses of BI 3968621 When Given Alone or With Ezabenlimab in Patients With Advanced Cancer

NCT07851103Advanced Solid Tumour

DrugEzabenlimab

Boehringer Ingelheim

Phase 1

Villejuif

2026-10-26

Recruiting

A Study of DS-3939a in Participants With Solid Tumors

NCT07739966Solid Tumor, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer

DrugsDS-1103a·DS-3939a·Pemetrexed·Carboplatin

Daiichi Sankyo

Phase 1/2

400

Marseille, Montpellier, Paris, Rennes, Saint-Herblain, Suresnes, Vandœuvre-lès-Nancy, Villejuif

2026-10-13

Recruiting

A Study to Test How Well Different Doses of BI 4060107 Are Tolerated by People With Advanced Cancer (Solid Tumours)

NCT07827144Solid Tumours

AIMEDBIO

Phase 1

Villejuif

2026-10-09

Not yet open

A Study of Selective Internal Radiation Therapy for the Management of Chemotherapy-induced Thrombocytopenia With Splenomegaly in Adult Subjects With Gastrointestinal Cancer

NCT07575854Gastrointestinal Cancer

Centre Georges Francois Leclerc

Not applicable

Dijon, Montpellier, Rennes, Villejuif

2026-10-01

Recruiting

A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35)

NCT07843940Extensive-stage Small Cell Lung Carcinoma, Advanced Small Cell Lung Cancer

DrugsObrixtamig·Pumitamig·Etoposide·Carboplatin

Boehringer Ingelheim

Phase 1/2

Lyon, Marseille, Villejuif

2026-10-01

Not yet open

Study to Evaluate the Efficacy of Zanzalintinib in the Treatment of Relapsed or Metastatic Adenoid Cystic Carcinomas of the Head and Neck

NCT07682675Adenoid Cystic Carcinoma of the Salivary Gland, Recurrence, Metastatic Disease

DrugZanzalintinib

UNICANCER

Phase 2

Toulouse, Villejuif

2026-10

Not yet open

A First-in-human Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Anti-tumour Activity of TAX2 in Patients With Relapsed/Refractory Advanced/Metastatic Solid Tumours

NCT07688148Solid Tumor Cancers

Apmonia Therapeutics

Phase 1/2

Lyon, Villejuif

2026-10

Recruiting

Bexmarilimab + Azacitidine Versus Placebo + Azacitidine in Participants With Treatment-naïve Higher-risk Myelodysplastic Syndromes

NCT07672769Higher Risk Myelodysplastic Syndromes

DrugsBexmarilimab·Azacitidine

Faron Pharmaceuticals Ltd

Phase 2

Bordeaux, Paris, Poitiers, Villejuif

2026-10

Recruiting

A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT07680764Locally Advanced Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer (NSCLC)

DrugsImzokitug·Pumitamig·Pemetrexed·Paclitaxel

Bristol-Myers Squibb

Phase 2

160

Nice, Montpellier, Villejuif, Grenoble, Marseille, Paris, Saint-Herblain

2026-09-10

Recruiting

Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)

NCT07680790Non-Small Cell Lung Cancer

DrugsIza-bren·Osimertinib·Pemetrexed·Cisplatin

Bristol-Myers Squibb

Phase 3

850

Marseille, Dijon, Nantes, La Tronche, Lyon, Paris, Bron, Villejuif

2026-09-08

Not yet open

Carboplatin-Enhanced Therapy in BRCA-Mutated or Neuroendocrine-Differentiated Aggressive Metastatic Castration-Sensitive Prostate Cancer

NCT07591467BRCA-Mutated, Neuroendocrine-Differentiated Aggressive Metastatic Castration-Sensitive Prostate Cancer, Prostate Cancer

Gustave Roussy, Cancer Campus, Grand Paris

Phase 3

330

Bordeaux, Lyon, Marseille, Nancy, Villejuif

2026-09

Not yet open

Preliminary Clinical Feasibility Study of a Medical Device Enabling Brain Access Using Microbubble-Enhanced Sonication

NCT07754006Recurrent Grade 4 Glioma, Brain Metastases From Extra-cranial Solid Tumors

Gustave Roussy, Cancer Campus, Grand Paris

Phase 1

Villejuif

2026-09

Not yet open

Adjuvant Trial in Pancreatic Neuroendocrine Tumors

NCT07591493Pancreatic Neuroendocrine Tumors (pNET), Pancreatic Neuroendocrine Tumors

Gustave Roussy, Cancer Campus, Grand Paris

Phase 3

300

Villejuif

2026-09

Not yet open

Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast Cancer

NCT07151586Triple Negative Breast Neoplasms, Neoplasm Metastasis, HER 2 Low-expressing Breast Cancer

DrugSacituzumab Govitecan

UNICANCER

Phase 2

260

Marseille, Villejuif

2026-09

Not yet open

Innovative and Cooperative Pathway Integrating Oncogeriatric, Pharmaceutical and Pharmacological Follow-up in Elderly Patients.

NCT07802847Elderly, Breast Cancer, Lung Cancer, Prostate Cancer

Gustave Roussy, Cancer Campus, Grand Paris

Phase 4

794

Villejuif

2026-09

Recruiting

Immunotherapy Master Trial for Advanced Cancers

NCT07431073Advanced / Metastatic Solid Tumors, Advanced Malignancy

UNICANCER

Phase 2

275

Villejuif

2026-08-21

Recruiting

Immunotherapy Without Chemotherapy for Advanced Lung Cancer Patients With High PD-L1 Levels

NCT07360743Non Small Cell Lung Cancer (Squamous or Non Squamous)

DrugsCemiplimab·Keytruda·Pembrolizumab

UNICANCER

Phase 2

275

Bordeaux, Boulogne-Billancourt, Nice, Villejuif

2026-08-21

Recruiting

A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

NCT07492680Solid Tumors

DrugsNavlimetostat·Pumitamig·Temozolomide·Cetuximab

Bristol-Myers Squibb

Phase 2

260

Dijon, Pierre-Bénite, Villejuif, Paris

2026-07-27

Active, closed

Personalizing Chemotherapy Selection After Surgery for Patients With Stage III Colorectal Cancer Using a Blood Test

NCT07340567Colorectal Cancer

DrugsFolfirinox·Folfox·Capecitabine·Oxaliplatin

UNICANCER

Phase 3

2,450

Villejuif

2026-07-20

Recruiting

A Study to Observe the Long-term Safety of Odevixibat in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing Treatment

NCT07585097Alagille Syndrome

Ipsen

Observational

Bron, Dijon, Le Kremlin-Bicêtre, Marseille, Montpellier, Paris, Toulouse, Villejuif

2026-07-10

Recruiting

DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

NCT07544654Extrapulmonary Neuroendocrine Cancer (epNEC)

DrugsObrixtamig·Etoposide·Carboplatin

Boehringer Ingelheim

Phase 3

390

Clichy, Dijon, Lyon, Marseille, Pessac, Rennes, Toulouse, Villejuif

2026-07-10

Recruiting

Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer

NCT07476287Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung Cancer, Lung Neoplasms

DrugPF-08634404

Pfizer

Phase 2

Lyon, Marseille, Villejuif

2026-07-02

Not yet open

KORTUC (KRC-01) Plus Radiotherapy for Organ Preservation in Rectal Cancer

NCT07622017Rectal Cancer

DrugsKortuc·Folfox·Capecitabine

Gustave Roussy, Cancer Campus, Grand Paris

Phase 2

Villejuif, Bordeaux

2026-07

Recruiting

A Study of ARC-02 in B-cell NHL

NCT07691606B-cell Non Hodgkin Lymphoma

DrugRituximab

Taiho Oncology, Inc.

Phase 1

140

Créteil, Lille, Lyon, Nantes, Villejuif

2026-06-22

Recruiting

A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202)

NCT07602777Sarcoma

DrugsRis-Rez·G-Csf

GlaxoSmithKline

Phase 1/2

Bordeaux, Lyon, Villejuif

2026-06-22

Recruiting

A Study to Evaluate Safety and Clinical Activity of GSK5926371 in Adult Participants With Relapsed or Refractory B-NHL

NCT07607925Lymphoma, Non-Hodgkin

DrugGSK5926371

GlaxoSmithKline

Phase 1/2

Pierre-Bénite, Rennes, Villejuif

2026-06-19

Active, closed

Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments

NCT07468071Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer, Advanced Solid Tumors Harboring the KRAS G12C Mutation

DrugsTNO155·Opnurasib·Trametinib·Cetuximab

Novartis Pharmaceuticals

Phase 1/2

Bron, Saint-Herblain, Villejuif

2026-06-08

Recruiting

BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease

NCT07492641HR+/HER2- Breast Cancer

DrugsBGB-43395·Ribociclib·Abemaciclib·Palbociclib

BeOne Medicines

Phase 3

1,056

Bordeaux, Lyon, Marseille, Montpellier, Rennes, SaintHerblain, Villejuif

2026-05-22

Recruiting

A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusions

NCT07422480Myelodysplastic Syndrome, Anemia

DrugsElritercept·Epoetin Alfa

Takeda

Phase 3

300

La Tronche, Poitiers, Villejuif, Nice, Paris

2026-05-21

Recruiting

A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis

NCT07387549Primary Sclerosing Cholangitis

DrugElafibranor

Ipsen

Phase 3

350

Lille, Lyon, Montpellier, Nantes, Paris, Toulouse, Villejuif

2026-05-14

Recruiting

A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer

NCT07287098Breast Neoplasms

DrugsImlunestrant·Goserelin·Tamoxifen

Eli Lilly and Company

Phase 2

600

Brest, Montpellier, Plérin, Saint-Cloud, Villejuif

2026-05-13

Recruiting

Study of INCA036978 in Participants With Myeloproliferative Neoplasms

NCT07441694Myeloproliferative Neoplasms

Incyte Corporation

Phase 1

218

Bordeaux, Paris, Villejuif

2026-05-11

Recruiting

A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)

NCT07549412Metastatic Colorectal Cancer

DrugsTrifluridine/Tipiracil·Bevacizumab

EMD Serono Research & Development Institute, Inc.

Phase 3

1,020

Bordeaux, Lille, Saint Priest En Jarez, Lyon, Villejuif, Paris

2026-05-06

Recruiting

Impact of Consumption of Ultra-processed Foods in Individuals at High Risk of Cancer

NCT07436312Breast Cancer, Pancreas Cancer, Colon Cancer, Lynch Syndrome

Gustave Roussy, Cancer Campus, Grand Paris

Not applicable

170

Avignon, Rennes, Villejuif

2026-05-04

Recruiting

AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

NCT07611110Metastatic Castration-resistant Prostate Cancer

DrugsDeutenzalutamide·Xofigo·FPI-2265·Cabazitaxel

AstraZeneca

Phase 3

670

Villejuif

2026-05-04

Recruiting

Establishing a Reference Framework for Outcomes After Machine-Preserved Liver Transplantation in Europe

NCT07585890End-stage Liver Disease (ESLD), Acute Liver Failure, Liver Cirrhosis, Liver Transplantation

University Medical Center Groningen

Observational

10,000

Clichy, Strasbourg, Villejuif

2026-04-21

Recruiting

Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)

NCT07531095Small Cell Lung Cancer

DrugsZL-1310·Tarlatamab·Durvalumab

Amgen

Phase 1

160

Bron, Marseille, Villejuif

2026-04-21

Recruiting

A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)

NCT07489495Carcinoma, Renal Cell

DrugsZanzalintinib·Belzutifan

Merck Sharp & Dohme LLC

Phase 3

758

Nice, Marseille, Toulouse, Angers, Le Mans, Saint Priest En Jarez, Villejuif

2026-04-09

Recruiting

AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors

NCT07403721Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR)

Amgen

Phase 1

464

Paris, Pierre-Bénite, Villejuif

2026-04-08

Recruiting

Phase 1 Study of PF-08046033 in Advanced Solid Tumors

NCT07519655Non-Small-Cell Lung, Esophageal Cancer, Cutaneous Melanoma

Pfizer

Phase 1

250

Toulouse, Villejuif

2026-04-08

Recruiting

Radiopharmaceutical Treatment of Advanced Kidney Cancer

NCT06783348Metastatic Clear Cell Renal Cell Carcinoma

DrugLu-PSMA

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2

Caen, Villejuif

2026-04-07

Recruiting

A Safety and Efficacy Study of hu14 in High-Risk Neuroblastoma Patients

NCT07549321High-Risk Neuroblastoma

DrugsTemozolomide·Irinotecan

Renaissance Pharma Ltd.

Phase 2/3

144

Paris, Villejuif

2026-03-30

Recruiting

A 2-part Phase 1/2 Open-label Trial on ODM-212

NCT07563738Mesothelioma, Pancreatic Cancer, NSCLC (Advanced Non-small Cell Lung Cancer)

DrugsODM-212·Gemcitabine and nab-paclitaxel·Ipilimumab and nivolumab·Sotorasib

Orion Corporation, Orion Pharma

Phase 1/2

229

Bordeaux, Marseille, Poitiers, Villejuif

2026-03-27

Recruiting

A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)

NCT07293351Advanced Renal Cell Carcinoma (RCC)

DrugsCasdatifan·Pumitamig·Cabozantinib·Yervoy

Bristol-Myers Squibb

Phase 1/2

474

Lille, Villejuif, Boredeaux

2026-03-26

Recruiting

Study Investigating ASP3082 in Patients With Metastatic/Locally Advanced Non-small-cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), With Biomarker Analysis to Characterize Response/Resistance

NCT07483983Metastatic/Locally Advanced Non-Small-Cell Lung Cancer, Metastatic/Locally Pancreatic Ductal Adenocarcinoma

DrugSetidegrasib

Gustave Roussy, Cancer Campus, Grand Paris

Phase 2

Villejuif, Bordeaux, Dijon, Marseille, Paris, Saint-Herblain, Vandœuvre-lès-Nancy

2026-03-25

Recruiting

Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)

NCT07405164Von Hippel-Lindau Disease, Malignant Neoplasms

DrugsBelzutifan·Cabozantinib·Lenvatinib·Nivolumab

Merck Sharp & Dohme LLC

Phase 3

450

Strasbourg, Toulouse, Villejuif

2026-03-23

Recruiting

First Time in Human (FTIH) Study to Investigate the Safety and Preliminary Activity of GSK5533524 Alone or in Combination in Adult Participants With Advanced Solid Tumors

NCT07438782Neoplasms

GlaxoSmithKline

Phase 1

Bordeaux, Villejuif

2026-03-23

Recruiting

Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure

NCT07219459Unresectable or Metastatic Hepatocellular Carcinoma, Child-Pugh A Hepatocellular Carcinoma, Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound

DrugsVisugromab RDE·Opdivo·Lenvatinib·Nivolumab

CatalYm GmbH

Phase 2

104

Pessac, Poitiers, Villejuif

2026-03-19

Recruiting

Cohort Evaluation of Body Fluids Early Detection of Cancer in High-risk Individuals

NCT06907095Risk of Breast Cancer, Risk of Gynaecological Cancer, Risk of Colorectal Cancer, Risk of Upper Gastrointestinal Cancers

Gustave Roussy, Cancer Campus, Grand Paris

Not applicable

5,909

Villejuif

2026-03-16

Recruiting

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

NCT07361497Non-small Cell Lung Cancer (NSCLC)

DrugsPumitamig·Durvalumab

Bristol-Myers Squibb

Phase 3

850

Bordeaux, Lyon Cedex08, Dijon, Montpellier, Saint-Herblain, Toulouse, Lille, Villejuif

2026-03-16

Recruiting

Effect of a Driving Pressure Adjustment Procedure for High-Frequency Jet Ventilation in Patients Undergoing Tumor Thermal Ablation in Interventional Radiology

NCT07408375Solid Tumor (Excluding CNS)

Nantes University Hospital

Not applicable

560

Lyon, Nantes, Nîmes, Paris, Poitiers, Saint-Herblain, Villejuif

2026-03-13

Recruiting

A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder

NCT07475806Muscle-invasive Bladder Cancer

DrugsEnfortumab Vedotin·Pembrolizumab

Astellas Pharma Global Development, Inc.

Phase 2

240

Cedex Lyon 08, Paris, Rennes, Strasbourg, Suresnes, Toulouse, Villejuif

2026-03-12

Recruiting

A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer

NCT07287150Metastatic Castration-Resistant Prostate Cancer

DrugsInavolisib·Abiraterone·Enzalutamide·Docetaxel

Hoffmann-La Roche

Phase 2

100

Bordeaux, Villejuif, Lyon, Marseille

2026-03-11

Recruiting

Exploration of Systemic and Portal Hemostasis in Patients Undergoing Transjugular Intrahepatic Portosystemic Shunt Placement

NCT07439939Liver Cirrhosis, Portal Hypertension

Assistance Publique - Hôpitaux de Paris

Observational

Villejuif

2026-03-09

Recruiting

Efficacy and Safety of the Valemetostat in Patients With Selected Solid Tumors.

NCT07303387Solid Tumor Malignancies, Clear Cell Endometrial Carcinoma, Ovarian Cancer

DrugValemetostat Tosylate

Gustave Roussy, Cancer Campus, Grand Paris

Phase 2

900

Villejuif, Bordeaux, Lyon, Paris

2026-03-05

Recruiting

Phase II Study of Ficerafusp Alfa in Combination With Nivolumab in Patients With Platinum-refractory Head and Neck Squamous Cell Carcinoma

NCT07529873Squamous Cell Carcinoma of Head and Neck (SCCHN)

DrugsFicerafusp alfa·Nivolumab

Groupe Oncologie Radiotherapie Tete et Cou

Phase 2

131

Villejuif

2026-03-03

Recruiting

Alpha Radiation Emitters Device (DaRT) for the Treatment of Locally Advanced Pancreatic Cancer

NCT06755359Pancreatic Cancer, Locally Advanced Pancreatic Cancer

Alpha Tau Medical LTD.

Not applicable

Bordeaux, Clermont-Ferrand, Dijon, Grenoble, Lyon, Marseille, Poitiers, Villejuif

2026-03-01

Not yet open

Comparison of 18F Labeled Analog of MIBG (18F-MFBG) PET/CT and 123I-MIBG SPECT in Pediatric Patients With Neuroblastoma.

NCT07111117Neuroblastoma

Institut Curie

Phase 2

Paris, Villejuif

2026-03-01

Recruiting

A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours)

NCT07306559Advanced Relapsed or Refractory Germ Cell Tumours, Advanced Relapsed or Refractory Endometrial Cancer, Advanced Relapsed or Refractory Ovarian Cancer

Boehringer Ingelheim

Phase 1

187

Marseille, Villejuif

2026-02-27

Recruiting

Evaluation of an Online Intervention to Educate Women at High Risk of Breast Cancer on How to Help Reduce Their Risk.

NCT07120087Breast Cancer

UNICANCER

Not applicable

1,508

Lyon, Villejuif

2026-02-19

Recruiting

A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

NCT07284758Multiple Myeloma, Relapsed/Refractory Multiple Myeloma

DrugsCemsidomide·Dexamethasone

C4 Therapeutics, Inc.

Phase 2

100

Bayonne, Lyon, Marseille, Rouen, Toulouse, Tours, Villejuif

2026-02-18

Recruiting

Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management

NCT07371585Breast Cancer Stage IV

DrugsPertuzumab·Trastuzumab deruxtecan

SOLTI Breast Cancer Research Group

Phase 2

300

Villejuif

2026-02-18

Recruiting

CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors

NCT07335497Locally Advanced / Metastatic Solid Tumors

DrugsTrifluridine and tipiracil·Gemcitabin·Folfox·Pemetrexed

Crescent Biopharma, Inc.

Phase 1/2

540

Villejuif

2026-02-17

Recruiting

First-Time-in-Human Study of GSK5471713 in Adults With mCRPC

NCT07332455Neoplasms, Prostate

GlaxoSmithKline

Phase 1/2

Montpellier, Villejuif

2026-02-10

Recruiting

A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies

NCT07213830Advanced Solid Tumor, Metastatic Solid Tumor

Ipsen

Phase 1/2

102

Villejuif

2026-02-06

Recruiting

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

NCT07431281Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer

DrugsSonesitatug Vedotin·Zolbetuximab·Rilvegostomig·Leucovorin

AstraZeneca

Phase 3

2,130

Bordeaux, Caen, Lyon, Marseille, Rennes, Villejuif

2026-02-03

Recruiting

Home Treatment of Patients With Active Cancer and Acute Pulmonary Embolism Without HESTIA Criteria.

NCT07315347Active Cancer and Symptomatic or Incidental Pulmonary Embolism Without HESTIA Criteria

Assistance Publique - Hôpitaux de Paris

Not applicable

824

Colombes, Dijon, Paris, Pierre-Bénite, Villejuif, Amiens, Angers, Brest

2026-02-02

Recruiting

A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer

NCT07258407Metastatic Castration-Resistant Prostatic Cancer

T.O.A.D. Oncology SA

Phase 1/2

180

Bordeaux, Paris, Villejuif

2026-01-30

Recruiting

A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma

NCT07219212Squamous Cell Carcinoma of Head and Neck

DrugsJNJ-90301900·Paclitaxel·Cisplatin·Carboplatin

Johnson & Johnson Enterprise Innovation Inc.

Phase 1

Brest, La Tronche, Lille, Marseille, Rouen, Villejuif

2026-01-26

Recruiting

Neo-adjuvant Immunotherapy Master Trial for Localized Cancers

NCT07262489Localized Cancer

UNICANCER

Phase 2

200

Villejuif

2026-01-21

Recruiting

A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies

NCT07220616Hematological Malignancies, B-cell Non-Hodgkin Lymphoma

Daiichi Sankyo

Phase 1/2

420

Lille, Pierre-Bénite, Villejuif

2026-01-16

Recruiting

Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

NCT07195695Non-small Cell Lung Cancer

DrugsZongertinib·Atezolizumab·Durvalumab·Nivolumab

Boehringer Ingelheim

Phase 3

400

Bron, Marseille, Nantes, Paris, Rennes, Strasbourg, Toulouse, Villejuif

2026-01-16

Recruiting

A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

NCT07195682Renal Cell Carcinoma

DrugsPumitamig·Yervoy·Ipilimumab

Bristol-Myers Squibb

Phase 1

281

Villejuif

2026-01-15

Recruiting

Neo-adjuvant Immunotherapy in Patients With Localized Melanoma

NCT07230613Cutaneous Melanoma, Stage III, Mucosal Melanoma

DrugsIpilimumab·Nivolumab

UNICANCER

Phase 2

Bordeaux, Lyon, Marseille, Paris, Villejuif

2026-01-12

Recruiting

Nasal Reconstruction FACE-Q : French Validation of the Nasal Reconstruction FACE-Q Questionnaire for Reconstruction/Rehabilitation Following Nasal Skin Cancer

NCT07257094Carcinoma

Hôpital NOVO

Observational

346

Caen, Nice, Paris, Pontoise, Toulon, Toulouse, Villejuif

2026-01-10

Recruiting

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT07222566Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)

DrugsPF-08634404·Pembrolizumab

Pfizer

Phase 3

1,410

Limoges, Angers, Paris, Vandœuvre-lès-Nancy, Villejuif, Boulogne-Billancourt

2026-01-06

Recruiting

A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

NCT07225946Prostatic Neoplasms, Castration-Resistant

DrugsPasritamig·Prednisone/Prednisolone·Docetaxel

Janssen Research & Development, LLC

Phase 3

800

Bordeaux, Clermont-Ferrand, Lille, Lyon, Nîmes, Paris, Rennes, Villejuif

2025-12-19

Recruiting

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

NCT07252232Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma (PDAC)

DrugCetuximab

Revolution Medicines, Inc.

Phase 3

500

Lille, Rennes, Villejuif, Marseille

2025-12-15

Not yet open

Normothermic Oxygenated Perfusion (NMP) Viability Testing Before Transplantation of Discarded Livers

NCT06950398Organ Transplantation, Liver Dysfunction, Liver Diseases

Rennes University Hospital

Phase 2

Clichy, Lyon, Montpellier, Rennes, Tours, Villejuif

2025-12-15

Recruiting

Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

NCT07222800Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasms, Neoplasms by Site

DrugsPF-08634404·Avastin·Bevacizumab

Pfizer

Phase 3

800

Villejuif, Brest, Dijon, Lille, Paris, Poitiers, Créteil

2025-12-11

Recruiting

A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)

NCT07222488Bladder Cancer, Urinary Bladder Neoplasms

DrugMK-3120

Merck Sharp & Dohme LLC

Phase 1/2

Villejuif

2025-12-09

Recruiting

Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer

NCT07226999Small Cell Lung Cancer (SCLC)

DrugsPF-08634404·Atezolizumab

Pfizer

Phase 2/3

550

Villejuif, Boulogne-Billancourt

2025-12-09

Recruiting

A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC

NCT07226986PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy

DrugsAbiraterone·Enzalutamide

Novartis Pharmaceuticals

Phase 1/2

123

Bordeaux, Clermont-Ferrand, Nantes, Villejuif

2025-12-05

Recruiting

A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours

NCT07213817Locally Advanced Solid Tumor, Metastatic Solid Tumor

Ipsen

Phase 1/2

114

Lyon, Saint-Herblain, Villejuif

2025-12-05

Recruiting

A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

NCT07276399Squamous Cell Carcinoma of Head and Neck

DrugsAmivantamab·Cisplatin·Carboplatin·Pembrolizumab

Janssen Research & Development, LLC

Phase 3

500

Avignon, Le Mans, Lille, Marseille, Paris, Rouen, Saint-Herblain, Villejuif

2025-12-03

Recruiting

A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy

NCT07218926Gastrointestinal Neoplasms

DrugsIDRX-42·Sunitinib

GlaxoSmithKline

Phase 3

450

Angers, Bordeaux, Lille, Lyon, Marseille, Saint-Herblain, Toulouse, Villejuif

2025-12-03

Not yet open

Study Assessing the Efficacy and Safety of cANnabidiol Oral Solution for Joint Pain of Adjuvant enDOcrine theRApy in Patients With Early Breast Cancer

NCT06787118Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III, HR+ Breast Cancer

DrugCBD oil

Gustave Roussy, Cancer Campus, Grand Paris

Phase 3

130

Villejuif

2025-12

Recruiting

Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer

NCT07001618NSCLC (Advanced Non-small Cell Lung Cancer)

DrugsCarboplatine·Pooled allogeneic fecal microbiotherapy·Vinorelbine·Cemiplimab

Gustave Roussy, Cancer Campus, Grand Paris

Phase 2

162

Dijon, Grenoble, Paris, Suresnes, Toulon, Villejuif

2025-11-17

Recruiting

Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers

NCT07259226Advanced Breast Cancer, Advanced Gastric Cancer, Advanced Urothelial Cancer, Advanced Non Small Cell Lung Cancer (NSCLC)

UNICANCER

Phase 2

400

Villejuif

2025-11-14

Recruiting

A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer

NCT07206225Non-muscle Invasive Bladder Cancer

DrugSasanlimab

Pfizer

Phase 1

294

Villejuif, Paris

2025-11-06

Recruiting

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

NCT07100080Non-Small Cell Lung Cancer

DrugsIza-bren·Pemetrexed·Cisplatin·Carboplatin

Bristol-Myers Squibb

Phase 2/3

500

Strasbourg, Toulouse, Lille, La Tronche, Saint-Herblain, Bron, Villejuif, Marseille

2025-11-05

Recruiting

A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate Cancer

NCT07189403Advanced or Metastatic Adrenocortical Carcinoma, Metastatic Castration-resistant Prostate Cancer

Daiichi Sankyo

Phase 1

Toulouse, Villejuif

2025-11-04

Recruiting

Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an Alteration of the HER2 Gene.

NCT07192068Non-Small Cell Lung Cancer, Sarcoma, Head &Amp; Neck Cancer, Colorectal Carcinoma

DrugZanidatamab

UNICANCER

Phase 2

105

Angers, Marseille, Vandœuvre-lès-Nancy, Villejuif

2025-10-30

Recruiting

A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors

NCT07213609Neoplasms, Colorectal, Neoplasms

GlaxoSmithKline

Phase 1/2

Lyon, Saint-Herblain, Villejuif

2025-10-20

Recruiting

Clinical Trial Comparing Induction Treatment With EGFR-ADC MRG003 Alone or in Combination With the Anti PD1 Pucotenlimab, Followed by Radiochemotherapy in Locally Advanced Squamous Cell Cancers of the Head and Neck

NCT06959108Locally Advanced Head and Neck Squamous Cell Carcinoma

DrugsPucotenlimab·Becotatug Vedotin

Groupe Oncologie Radiotherapie Tete et Cou

Phase 2

106

Villejuif

2025-10-13

Recruiting

A Study of JNJ-89862175 for Treatment of Advanced Solid Tumors

NCT07223125Advanced-stage Solid Tumors

Janssen Research & Development, LLC

Phase 1

360

Lyon, Villejuif

2025-10-10

Recruiting

A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

NCT07100106Breast Cancer

DrugsRGT-419B·Giredestrant·Abemaciclib

Genentech, Inc.

Phase 1/2

285

Reims, Villejuif, Caen, Lille, Rennes

2025-10-07

Recruiting

A Short-term Preoperative, Evaluating Activity and Safety of Elacestrant Monotherapy as Compared to Elacestrant + Ovarian Function Suppression (LHRH Agonist) in Premenopausal Patients With Stage I-II ER+/HER2- Breast Cancer

NCT07159451Breast Cancer

DrugsLeuprorelin·Elacestrant

Gustave Roussy, Cancer Campus, Grand Paris

Phase 2

140

Villejuif

2025-10-06

Recruiting

A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

NCT06989437Cachexia, Metastatic Pancreatic Ductal Adenocarcinoma

DrugPonsegromab

Pfizer

Phase 2/3

982

Marseille, Créteil, Villejuif, Poitiers

2025-10-03

Recruiting

Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer

NCT07181161Metastatic Prostate Cancer

DrugPalacaparib

AstraZeneca

Phase 1/2

283

Lyon, Montpellier, Saint-Herblain, Suresnes, Villejuif

2025-10-01

Recruiting

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

NCT07144280Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Carcinoma

DrugsPF-08046054·Docetaxel

Pfizer

Phase 3

680

Brest, Toulouse, Rennes, Saint-Herblain, Lille, Villejuif, Bordeaux, Marseille

2025-09-29

Recruiting

This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

NCT07028853Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate

DrugsMevrometostat·Xtandi·Enzalutamide

Pfizer

Phase 3

1,000

Bordeaux, Lyon Cedex08, Brest, Besançon, Reims, Bayonne, Pierre-Bénite, Villejuif

2025-09-28

Recruiting

Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors

NCT06441331Somatostatin Receptor Positive, NETs, Lymphoma, Solid Tumor

Drug177Lu-edotreotide

ITM Solucin GmbH

Phase 1

Marseille, Villejuif

2025-09-26

Recruiting

A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)

NCT07140016Non-small Cell Lung Cancer (NSCLC), Anaplastic Lymphoma Kinase (ALK) Positive

DrugGilteritinib

Astellas Pharma Global Development, Inc.

Phase 1

Saint-Herblain, Toulouse, Villejuif

2025-09-22

Recruiting

A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer

NCT06919965Non-Muscle Invasive Bladder Neoplasms

DrugsErdafitinib·Mitomycin C·Gemcitabine

Janssen Research & Development, LLC

Phase 3

220

Marseille, Paris, Quint-Fonsegrives, Saint-Grégoire, Villejuif

2025-09-10

Recruiting

A Study to Determine the Efficacy of a Digital Self-management Support Tool to Improve the Quality of Life During Adjuvant HOrmonal Therapy for Patients With Early Breast Cancer

NCT06781996Breast Cancer, Breast Cancer Early Stage Breast Cancer (Stage 1-3)

Gustave Roussy, Cancer Campus, Grand Paris

Phase 3

180

Villejuif

2025-09-09

Recruiting

First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients.

NCT06840782Oligometastatic Non-small Cell Lung Cancer (NSCLC)

Gustave Roussy, Cancer Campus, Grand Paris

Phase 3

124

Creil, Avignon, Villejuif

2025-09-09

Recruiting

Efficacy of Intraoperative Use of 20% Albumin Combined With Ringer Lactate Versus Ringer Lactate During Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy

NCT06351475Peritoneal Neoplasms, Hyperthermic Intraperitoneal Chemotherapy, Intraoperative Care, Fluid Therapy

Assistance Publique - Hôpitaux de Paris

Not applicable

140

Lyon, Montpellier, Paris, Reims, Strasbourg, Villejuif

2025-09-03

Recruiting

STEpwise Research Program to Promote INGeniouS ONline Supportive Solutions in the Relief of Cancer-related Fatigue

NCT06505590Cancer Diagnosis, Moderate or Severe Score of Cancer-related Fatigue (CRF)

Gustave Roussy, Cancer Campus, Grand Paris

Not applicable

372

Villejuif

2025-09-01

Not yet open

Evaluation of the Superficial Cervical Plexus Block in Oncological Throat and Neck Surgery

NCT07110857ENT Cancers

Assistance Publique - Hôpitaux de Paris

Not applicable

346

Lille, Marseille, Paris, Rouen, Suresnes, Villejuif

2025-09

Not yet open

A Multicenter Trial Evaluating Efficacy and Safety of A Reduced Venetoclax Exposure To Seven Days Versus Standard Continuous Venetoclax Exposure Combined With Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Intensive Induction

NCT07082452Leukemia, B-Cell, Chronic, Leukemia

DrugsAzacitidine·Venetoclax

Gustave Roussy, Cancer Campus, Grand Paris

Phase 3

262

Villejuif

2025-09

Recruiting

A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors

NCT07169734Cervical Squamous Cell Carcinoma, Squamous Non-small-cell Lung Cancer, Colorectal Cancer, Intrahepatic Cholangiocarcinoma

Alentis Therapeutics AG

Phase 1/2

180

Dijon, Marseille, Toulouse, Villejuif

2025-08-26

Recruiting

Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors

NCT07151040Solid Tumor, Colorectal Cancer (CRC), Squamous Cell Carcinoma of Head and Neck, Non-Small Cell Lung Cancer (NSCLC)

One-carbon Therapeutics AB

Phase 1/2

Villejuif

2025-08-22

Recruiting

A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]

NCT07099898Neoplasms, Lung

DrugsRisvutatug rezetecan·Ris-Rez·Topotecan

GlaxoSmithKline

Phase 3

420

Boulogne-Billancourt, Grenoble, Saint-Herblain, Villejuif

2025-08-11

Recruiting

Safety and Efficacy Study of Zamtocabtagene Autoleucel (MB-CART2019.1) in Pediatric Patients With R/R B-Cell Neoplasms

NCT06508931B-Cell Neoplasm

DrugZamtocabtagene autoleucel

Miltenyi Biomedicine GmbH

Phase 2

Paris, Villejuif

2025-08-04

Recruiting

AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors

NCT07094113KRAS Altered Advanced or Metastatic Solid Tumors

DrugsPanitumumab·Pembrolizumab

Amgen

Phase 1

434

Lyon, Villejuif

2025-07-31

Recruiting

A Study of LY4175408 in Participants With Advanced Cancer

NCT07046923Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Endometrial Neoplasms, Neoplasm Metastasis

DrugsCisplatin·Carboplatin·Pembrolizumab

Eli Lilly and Company

Phase 1

240

Lyon, Villejuif

2025-07-28

Recruiting

A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors

NCT07094204Solid Tumor, Non-Small-Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer

DrugPanitumumab

Astellas Pharma Inc

Phase 1

404

Bordeaux, Lyon, Pierre-Bénite, Villejuif

2025-07-25

Recruiting

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

NCT06757634Breast Cancer

DrugsGedatolisib·Ribociclib·Palbociclib·Letrozole

Celcuity Inc

Phase 3

1,180

Amiens, Caen, Dijon, Le Mans, Marseille, Pierre-Bénite, Poitiers, Villejuif

2025-07-24

Recruiting

Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer

NCT06606730Breast Cancers, Triple Negative Breast Cancer (TNBC)

DrugsKeytruda·Pembrolizumab

UNICANCER

Phase 3

2,454

Villejuif

2025-07-23

Recruiting

Oral Arsenic (ATO) in Low-risk Myelodysplastic Syndromes (MDS)

NCT06670222Low-risk Myelodysplastic Syndromes

DrugArsenic Trioxide

Groupe Francophone des Myelodysplasies

Phase 1

Nice, Paris, Villejuif

2025-07-22

Active, closed

A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer

NCT06888921Ovarian Cancer, Ovarian Cancer Recurrent

Compugen Ltd

Phase 1/2

Besançon, Toulouse, Lille, Marseille, Pierre-Bénite, Rennes, Saint-Herblain, Villejuif

2025-07-21

Recruiting

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

NCT07060807Breast Neoplasms

DrugsPatritumab deruxtecan·Pegylated liposomal doxorubicin·Abraxane·Xeloda

Merck Sharp & Dohme LLC

Phase 3

1,000

Brest, Lyon, Rouen, Villejuif

2025-07-21

Recruiting

Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)

NCT07049926Renal Cell Carcinoma

DrugsZanzalintinib·Belzutifan

Merck Sharp & Dohme LLC

Phase 1/2

140

Strasbourg, Toulouse, Rennes, Vandœuvre-lès-Nancy, Villejuif

2025-07-20

Recruiting

Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB)

NCT07016230Metastatic/Locally Advanced Small-Cell Lung Cancer, Metastatic/Locally Advanced Poorly Differentiated NEC

DrugTarlatamab

Gustave Roussy, Cancer Campus, Grand Paris

Phase 2

Bordeaux, Nice, Villejuif

2025-07-02

Recruiting

Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid Tumors

NCT06819735Advanced Solid Tumors

DrugDT-7012

Domain Therapeutics Australia Pty Ltd

Phase 1/2

125

Bordeaux, Strasbourg, Villejuif

2025-06-25

Recruiting

A Phase 2 Study to Assess STP938 (Dencatistat) as a Monotherapy in Adults With High Risk Essential Thrombocythaemia - The VECTRA Trial

NCT06786234Essential Thrombocythaemia

DrugSTP938

Step Pharma, SAS

Phase 2

Poitiers, Brest, Marseille, Nantes, Nice, Nîmes, Paris, Villejuif

2025-06-18

Recruiting

First-in-human Trial of STC-1010, an Immunotherapy, in Patients With Unresectable Locally Advanced or Metastatic Colorectal Cancer

NCT06934538Unresectable Metastatic Colorectal Cancer, Unresectable Locally Advanced Colorectal Cancer

Brenus Pharma

Phase 1/2

Bordeaux, Dijon, Lyon, Montpellier, Poitiers, Villejuif

2025-06-17

Recruiting

A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer

NCT06990880Neoplasms, Prostate

GlaxoSmithKline

Phase 1/2

Lyon, Villejuif

2025-06-12

Recruiting

Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors

NCT06878664Grade1-2 Advanced Midgut Neuroendocrine Tumors (NETs)

DrugsAmino acid·Lanreotide·Octreotide LAR·Lutathera

Grupo Espanol de Tumores Neuroendocrinos

Phase 3

166

Caen, Dijon, Lille, Lyon, Marseille, Clichy, Paris, Villejuif

2025-06-12

Recruiting

A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)

NCT06885034Gastrointestinal Neoplasms

DrugRisvutatug rezetecan

GlaxoSmithKline

Phase 1/2

346

Dijon, Marseille, Paris, Poitiers, Rennes, Villejuif

2025-06-11

Not yet open

SIRT and Peri-immunotherapy : a New Concept

NCT06971237Advanced Hepatocellular Carcinoma (HCC), Classified as BCLC Stage B or C, Treated With a Combination of Selective Internal Radiation Therapy

DrugAtezolizumab & Bevacizumab

Assistance Publique - Hôpitaux de Paris

Observational

Villejuif

2025-06-01

Recruiting

A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)

NCT06961006Malignant Melanoma

DrugsIntismeran autogene·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 2

160

Nice, Paris, Villejuif

2025-05-29

Recruiting

Intermittent Androgen Deprivation Therapy in the Era of AR Pathway Inhibitors

NCT05974774Prostate Cancer

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3

1,600

Caen, Grenoble, Quint-Fonsegrives, Toulouse, Villejuif

2025-05-23

Recruiting

A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype

NCT06522737Lymphoma

DrugsDuvelisib·Bendamustine·Gemcitabine

SecuraBio

Phase 3

124

Rouen, Villejuif, Caen, Clermont-Ferrand, Montpellier, Nantes, Paris, Pessac

2025-05-19

Active, closed

Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)

NCT06898957Small Cell Lung Cancer

DrugsTam-Peli·Tarlatamab·Durvalumab

Amgen

Phase 1

Bordeaux, Lyon, Toulouse, Villejuif

2025-05-16

Recruiting

Cabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma

NCT06934057Kidney Cancer, Renal Cell Cancer

DrugsCabozantinib·Opdivo·Nivolumab

Gustave Roussy, Cancer Campus, Grand Paris

Phase 4

Angers, Dijon, Lyon, Paris, Toulouse, Tours, Villejuif

2025-05-16

Active, closed

A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone

NCT06806852Head and Neck Squamous Cell Carcinoma

DrugsBI 770371·Cetuximab·Pembrolizumab

Boehringer Ingelheim

Phase 1

Lille, Lyon, Marseille, Villejuif

2025-05-14

Recruiting

Safety of HRX215 in Patients After Minor and Major Liver Resection

NCT06638502Liver Resection, Colorectal Carcinoma Liver Metastases

HepaRegeniX GmbH

Phase 1/2

Lille, Villejuif

2025-05-06

Not yet open

Analysis of Risk Factors for Hearing Loss in Survivors of Cancer Occurred During Childhood, Adolescence or Young Adulthood

NCT06957132Ototoxicity, Drug-Induced, Ototoxicity, Radiation-Induced, Pediatric Cancer

Gustave Roussy, Cancer Campus, Grand Paris

Not applicable

500

Paris, Villejuif

2025-05

Recruiting

tislelizUMaB in canceR Patients With molEcuLar residuaL Disease

NCT06332274Cancer, Lung Cancer, Colo-rectal Cancer, Pancreas Cancer

DrugTislelizumab

Gustave Roussy, Cancer Campus, Grand Paris

Phase 3

717

Villejuif

2025-04-16

Recruiting

Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors

NCT06795412Advanced Solid Tumors

DrugsPYX-201·Keytruda·Pembrolizumab

Pyxis Oncology, Inc

Phase 1/2

220

Bordeaux, Lyon, Marseille, Villejuif

2025-04-15

Recruiting

Preoperative Magnetic Tracking in Breast Surgery in France: French Medical-economic Study.

NCT06906601Breast Cancer, Medico-economic Impact, Breast Cancer Surgery

Centre Leon Berard

Observational

772

Lyon, Nancy, Pontoise, Reims, Rennes, Villejuif

2025-04-15

Recruiting

Study Evaluating the Efficacy and Safety of Darolutamide and Stereotactic Dose Escalated Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse

NCT06625970High Risk Prostate Carcinoma, Prostate Cancer

DrugDarolutamide

UNICANCER

Phase 3

700

Brest, Dijon, Paris, Saint-Etienne, Villejuif

2025-04-10

Recruiting

Evaluation of Software for Interpreting Virological Results Indicated for the Diagnosis of Cytomegalovirus (CMV) Infection During Pregnancy and Intended for Health Professionals

NCT06694428Cytomegalovirus Infections, Maternal Primary Cytomegalovirus Infection

Assistance Publique - Hôpitaux de Paris

Observational

491

Limoges, Paris, Villejuif

2025-04-04

Active, closed

A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005)

NCT06864169Gastrointestinal Cancer

DrugR-DXd

Merck Sharp & Dohme LLC

Phase 2

160

Caen, Montpellier, Villejuif, Paris

2025-04-01

Recruiting

BOne Metastases REgistry for Patients Undergoing cryoAbLation With curatIve purpoSe

NCT06480955Bone Metastases

Cardiovascular and Interventional Radiological Society of Europe

Observational

Bordeaux, Strasbourg, Villejuif

2025-04-01

Recruiting

Influence of Human Albumin Supplementation on Kidney Dysfunction After Liver Transplantation

NCT06535945Liver Transplantation, Acute Kidney Injury

Rennes University Hospital

Phase 4

400

Chambray-lès-Tours, Clichy, Lille, Lyon, Montpellier, Pessac, Rennes, Villejuif

2025-03-26

Recruiting

A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)

NCT06818643Advanced Solid Tumors, Malignant Neoplasm

DrugMK-3120

Merck Sharp & Dohme LLC

Phase 1/2

270

Marseille, Rennes, Lille, Villejuif

2025-03-25

Active, closed

A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours

NCT06833008Advanced Solid Tumor

Ipsen

Phase 1/2

Lyon, Paris, Villejuif

2025-03-14

Active, closed

A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer

NCT06764485Metastatic Castration-resistant Prostate Cancer

DrugsAbiraterone·Enzalutamide·Docetaxel

Celgene

Phase 3

960

Nice, Dijon, Toulouse, Vandœuvre-lès-Nancy, Pierre-Bénite, Le Mans, Villejuif, Clermont-Ferrand

2025-03-13

Active, closed

A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer

NCT06792695Metastatic Colorectal Cancer

DrugsFOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan)·Volrustomig·Bevacizumab

AstraZeneca

Phase 2

Montpellier, Poitiers, Saint-Priez En Jarez, Villejuif

2025-03-12

Recruiting

Microbiota Modification for Immuno-oncology in Hepatocellular Carcinoma

NCT06551272Hepatocellular Carcinoma

DrugEXL01

Center Eugene Marquis

Phase 2

Bobigny, Bordeaux, Clichy, Nantes, Rennes, Villejuif

2025-03-12

Recruiting

177Lu-DOTATATE for Recurrent Meningioma

NCT06326190Recurrent Meningioma

DrugsLuTate·Lutathera

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2

136

Lyon, Marseille, Rennes, Toulouse, Vandœuvre-lès-Nancy, Villejuif

2025-03-10

Active, closed

A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer

NCT06521567Melanoma, Hodgkin Lymphoma, High and Low Grade Glioma, Glioblastoma Multiforme (GBM)

DrugsCobolimab·Dostarlimab

GlaxoSmithKline

Phase 1/2

Bordeaux, Lyon, Paris, Strasbourg, Villejuif

2025-03-06

Recruiting

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

NCT06772623Non Small Cell Lung Carcinoma, c-MET

DrugsBudigalimab·Telisotuzumab Adizutecan·Pemetrexed·Cisplatin

AbbVie

Phase 1/2

252

Bordeaux, Saint-Herblain, Montpellier, Nice, Villejuif, Paris

2025-03-06

Recruiting

A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2)

NCT06796907Tumours, Gynecological

DrugsMo-Rez·Dostarlimab·Bevacizumab

GlaxoSmithKline

Phase 1/2

305

Lyon, Marseille, Montpellier, Pierre-Bénite, Villejuif

2025-03-04

Recruiting

A First-in-human Study to Learn About the Safety of BAY 3547926 and How Well it Works in Participants With Advanced Liver Cancer

NCT06764316Hepatocellular Carcinoma

Bayer

Phase 1

148

Montpellier, Bron, Nantes, Villejuif

2025-02-28

Recruiting

A Phase 1 Study of IM-1021 in Participants With Advanced Cancer

NCT06823167Solid Malignancies, Hematologic Malignancies

Immunome, Inc.

Phase 1

190

Lyon, Paris, Villejuif

2025-02-26

Recruiting

A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

NCT06646276Extensive-Stage Small Cell Lung Cancer

DrugsEtoposide·Atezolizumab·Nivolumab·Carboplatin

Bristol-Myers Squibb

Phase 3

530

Montpellier, La Tronche, Lille, Gleizé, Pierre-Bénite, Créteil, Villejuif, Marseille

2025-02-25

Recruiting

Lymphocyte-Sparing And Radio-Immunotherapy in Head and Neck Carcinoma

NCT06706401Oropharynx Cancer, Larynx Cancer, Hypopharynx Cancer, Primary Head and Neck Tumor

DrugsVesanoid·ATRA·Cetuximab·Cisplatin

Centre Leon Berard

Phase 3

460

Lyon, Vandœuvre-lès-Nancy, Villejuif, Angers, Lille, Nice, Paris, Reims

2025-02-20

Recruiting

A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors

NCT06697197Advanced Solid Tumors

DrugPumitamig

Bristol-Myers Squibb

Phase 1/2

286

Marseille, Villejuif

2025-02-17

Recruiting

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

NCT06760819Advanced Solid Tumors, HER2 Mutation

DrugSevabertinib

Bayer

Phase 2

111

Pierre-Bénite, Brest, Lille, Bordeaux, Montpellier, Villejuif

2025-02-13

Recruiting

Rehabilitation Improved by Early Detection of Fisyulas Post (Pharyngo) -Total Laryngectomy by Cytokine Measurement on Drainage Fluid on the Second Post-Operative Day

NCT06604494Cancer, Otorhinolaryngeal

University Hospital, Clermont-Ferrand

Not applicable

250

Clermont-Ferrand, Grenoble, Le Puy-en-Velay, Lyon, Saint-Etienne, Valence, Villejuif

2025-02-12

Active, closed

Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer

NCT06619236Platinum-resistant Ovarian Cancer

DrugsRina-S·Pegylated liposomal doxorubicin·Topotecan·Gemcitabine

Genmab

Phase 3

584

Nice, Paris, Pierre-Bénite, Rennes, Saint-Herblain, Toulouse, Villejuif

2025-02-07

Recruiting

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

NCT06618287Lung Cancer, Breast Cancer

DrugsPumitamig·Iza-bren·Osimertinib·Opdivo

Bristol-Myers Squibb

Phase 1/2

416

Nice, Bordeaux, Lyon, Marseille, Caen, Montpellier, Villejuif, Paris

2025-02-04

Recruiting

A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

NCT06564038Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma, Large B-cell Lymphoma

DrugsSurovatamig·Acalabrutinib·Vincristine·Doxorubicin

AstraZeneca

Phase 1/2

408

Clermont-Ferrand, Montpellier, Paris, Saint-Cloud, Villejuif

2025-01-30

Active, closed

Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)

NCT06710132Solid Tumors, Gastric Cancer, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer

DrugM9140

EMD Serono Research & Development Institute, Inc.

Phase 1/2

184

Bordeaux, Dijon, Lille, Paris, Saint-Herblain, Suresnes, Toulouse, Villejuif

2025-01-29

Active, closed

Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors

NCT06781983Advanced or Metastatic Solid Tumors

Innate Pharma

Phase 1

145

Lyon, Villejuif

2025-01-24

Active, closed

Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)

NCT06632951Urothelial Carcinoma

DrugsLivmoniplimab·Budigalimab·Docetaxel·Gemcitabine

AbbVie

Phase 2

150

Marseille, Suresnes, Villejuif

2025-01-20

Recruiting

SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

NCT06743126Melanoma, Cutaneous Malignant, Mucosal Melanoma

DrugsAnzu-cel·Lifileucel·Temodar·Dacarbazine

Immatics US, Inc.

Phase 3

450

Lille, Paris, Villejuif

2025-01-14

Recruiting

An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors

NCT06589596Advanced Solid Tumor

DrugBGB-58067

BeOne Medicines

Phase 1

695

Bordeaux, Marseille, Paris, Saint-Herblain, Villejuif

2025-01-10

By invitation

A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring

NCT06788509Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes

DrugsJNJ-75348780·JNJ-87801493·JNJ-80948543·Ibrutinib

Janssen Research & Development, LLC

Phase 1

120

Lille, Nantes, Villejuif

2024-12-30

Recruiting

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)

NCT06637423Non-Muscle Invasive Bladder Cancer

DrugSacituzumab tirumotecan

Merck Sharp & Dohme LLC

Phase 1/2

Lille, Créteil, Villejuif

2024-12-20

Recruiting

A Study to Investigate ALE.P02 as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Selected CLDN1+ Solid Tumors

NCT06747585Squamous Non-small-cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma

DrugPembrolizumab

Alentis Therapeutics AG

Phase 1/2

235

Bordeaux, Dijon, Lille, Marseille, Toulouse, Villejuif

2024-12-16

Recruiting

Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors

NCT06784193Advanced or Metastatic ER+ HER2- Breast Cancer (mBC), Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC), Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC), Metastatic Breast Cancer

DrugsPalazestrant·Fulvestrant

Olema Pharmaceuticals, Inc.

Phase 1

180

Saint-Herblain, Paris, Villejuif

2024-12-16

Recruiting

A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

NCT06679101Multiple Myeloma, Newly Diagnosed Multiple Myeloma

DrugsBelantamab mafodotin·Daratumumab·Lenalidomide·Dexamethasone

GlaxoSmithKline

Phase 3

520

Bobigny, Nantes, Villejuif

2024-12-16

Active, closed

Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

NCT06608927Metastatic Pancreatic Ductal Adenocarcinoma

DrugsQuemliclustat·Nab-paclitaxel·Gemcitabine

Arcus Biosciences, Inc.

Phase 3

610

Dijon, Lille, Lyon, Poitiers, Villejuif

2024-12-13

Recruiting

First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

NCT06657222Advanced Solid Tumors, HNSCC, SCLC, NSCLC

Gilead Sciences

Phase 1/2

250

Paris, Villejuif

2024-12-13

Recruiting

A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

NCT06667908Carcinoma, Non-Small-Cell Lung

DrugsJNJ-90301900·Durvalumab

Johnson & Johnson Enterprise Innovation Inc.

Phase 2

130

Brest, Marseille, Paris, Rouen, Villejuif

2024-12-06

Active, closed

Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)

NCT06635824PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC

DrugsDocetaxel·Pembrolizumab

Genmab

Phase 3

191

Marseille, Bordeaux, Bayonne, Avignon, Villejuif, Angers, Boulogne-Billancourt, Créteil

2024-11-25

Recruiting

Evaluation of Medical and Social Care for Elderly Patients, Between Hospital and Home: TEMPORARY ACCOMMODATION Out of Hospitalization by Nursing Home and Long-Term Care Units in Ile-de-France Region

NCT06677645Social Care, Medical Care, Elderly Patients

Gérond'if

Observational

258

Cormeilles-en-Parisis, L'Haÿ-les-Roses, Melun, Paris, Rambouillet, Versailles, Villejuif

2024-11-20

Recruiting

CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.

NCT06690775Epithelial Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancer, Endometrioid Ovarian Cancer

DrugsTORL-1-23·Pegfilgrastim

TORL Biotherapeutics, LLC

Phase 2

230

Lyon, Saint-Herblain, Villejuif

2024-11-20

Recruiting

A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors

NCT06619587Solid Tumor

Genentech, Inc.

Phase 1

410

Villejuif, Bordeaux, Dijon

2024-11-14

Active, closed

A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)

NCT06719141Developmental and Epileptic Encephalopathy

DrugBexicaserin

Longboard Pharmaceuticals

Phase 3

367

Lille, Toulouse, Bron, Marseille, Paris, Strasbourg, Villejuif

2024-11-11

Recruiting

Study of IMC-P115C in Advanced PRAME-Positive Cancers

NCT07156136PRAME Positive, Cancer, HLA-A*02:01-positive

Immunocore Ltd

Phase 1

140

Lyon, Toulouse, Villejuif

2024-11-07

Recruiting

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

NCT06625775Solid Tumor, Adult, Metastatic Breast Cancer, Advanced Breast Cancer, HER2 Mutation-Related Tumors

DrugsBBO-10203·Ribociclib·Folfox·Fulvestrant

TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

Phase 1

392

Montpellier, Saint-Cloud, Saint-Herblain, Bordeaux, Lyon, Villejuif

2024-10-29

Active, closed

A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy

NCT06413706Glioma

DrugsAbemaciclib·Temozolomide

Eli Lilly and Company

Phase 2

Bordeaux, Lille, Lyon, Marseille, Paris, Villejuif

2024-10-25

Recruiting

FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations

NCT06669117Solid Tumor, MET Alteration

Pierre Fabre Medicament

Phase 1/2

140

Marseille, Saint-Herblain, Toulouse, Villejuif

2024-10-22

Recruiting

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

NCT06623422Carcinoma, Non-Small-Cell Lung

DrugsIntismeran autogene·Platinol·Paraplatin·Taxol

Merck Sharp & Dohme LLC

Phase 3

680

Caen, Tours, Besançon, Saint-Herblain, Lille, Lyon, Paris, Villejuif

2024-10-21

Active, closed

Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

NCT06625320Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma

DrugsLiposomal Irinotecan·Leucovorin·Irinotecan·Cetuximab

Revolution Medicines, Inc.

Phase 3

500

Marseille, Rennes, Villejuif

2024-10-16

Recruiting

Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

NCT06562192Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, HR+/HER2- Ductal and Lobular Breast Cancer, Triple Negative Breast Cancer

Novartis Pharmaceuticals

Phase 1

162

Bron, Villejuif

2024-10-15

Recruiting

Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations

NCT06581432Solid Tumours

DrugZongertinib

Boehringer Ingelheim

Phase 2

588

Bordeaux, Dijon, Lyon, Marseille, Poitiers, Villejuif

2024-10-11

Recruiting

Treatment With Darolutamide +/- Radiation Therapy for Patients With a Castration Resistant Cancer and Metastases Detected by Functional Imaging

NCT06276465Prostatic Cancer, Castration-Resistant

DrugDarolutamide

UNICANCER

Phase 3

336

Lorient, Mougins, Saint-Etienne, Villejuif

2024-10-07

Recruiting

A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)

NCT06551142Neoplasms

DrugsRis-Rez·Tarlatamab·Dostarlimab·Cetuximab

GlaxoSmithKline

Phase 1

845

Bordeaux, Lyon, Villejuif

2024-09-30

Active, closed

Prospective Analysis of Circulating Nucleosomes in Patients Receiving a First Line Treatment for a Non-Hodgkin Lymphoma

NCT06813573Follicular Lymphoma, Diffuse Large B-Cell Lymphoma

DrugBlood sampling

Gustave Roussy, Cancer Campus, Grand Paris

Not applicable

Villejuif

2024-09-30

Active, closed

A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)

NCT06660394Dravet Syndrome

DrugBexicaserin

Longboard Pharmaceuticals

Phase 3

108

Bron, Lille, Toulouse, Marseille, Paris, Strasbourg, Villejuif

2024-09-25

Recruiting

A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

NCT06561685Metastatic Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer, SMARCA4-Deficient Tumor

DrugsNab-paclitaxel·Pemetrexed·Paclitaxel·Cisplatin

Eli Lilly and Company

Phase 1

340

Bordeaux, Paris, Villejuif

2024-09-19

Recruiting

A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

NCT06542250B-cell Malignancies

DrugAZD5492

AstraZeneca

Phase 1/2

174

Pessac, Villejuif

2024-09-18

Active, closed

Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).

NCT06333951Thoracic Tumors, Non-small Cell Lung Cancer

DrugsAnvumetostat·Sotorasib·Pemetrexed·Paclitaxel

Amgen

Phase 1

Bordeaux, Marseille, Saint-Herblain, Villejuif

2024-09-17

Recruiting

Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs

NCT06567015Non-small Cell Lung Cancer (NSCLC)

Pierre Fabre Medicament

Phase 1/2

171

Lyon, Marseille, Saint-Herblain, Toulouse, Villejuif

2024-09-17

Active, closed

Efficacy of a Systematic Referral to Palliative Care of Patients Who Need for Palliative Care During an Unscheduled Visit in Comprehensive Anticancer Centers

NCT06150027Cancer, Emergencies

Centre Leon Berard

Not applicable

240

Lyon, Montpellier, Paris, Saint-Cloud, Vandœuvre-lès-Nancy, Villejuif

2024-09-12

Active, closed

MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

NCT06586515Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer

DrugsLeucovorin·Irinotecan·Cetuximab·Adrucil

Eli Lilly and Company

Phase 1

630

Lyon, Marseille, Toulouse, Villejuif

2024-09-12

Recruiting

A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.

NCT06476808High-grade Serous Ovarian Carcinoma (HGSOC), Uterine Serous Carcinoma (USC), Non-small Cell Lung Cancer (NSCLC)

Bristol-Myers Squibb

Phase 1

240

Bordeaux, Villejuif, Lyon

2024-09-06

Active, closed

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)

NCT06486441Endometrial Cancer

DrugsAdriamycin·Sacituzumab Govitecan·Taxol·Doxorubicin

Gilead Sciences

Phase 3

640

Caen, Marseille, Nice, Paris, Pierre-Bénite, Saint-Herblain, Vandœuvre-lès-Nancy, Villejuif

2024-08-28

Active, closed

A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors

NCT06533059Cancer, Breast Cancer, Endometrial Cancer, Metastatic Cancer

Alterome Therapeutics, Inc.

Phase 1

110

Caen, Villejuif

2024-08-22

Recruiting

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

NCT06395103B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma, Neuroblastoma

DrugZilovertamab vedotin

Merck Sharp & Dohme LLC

Phase 1/2

Bordeaux, Lyon, Nantes, Marseille, Villejuif

2024-08-16

Active, closed

A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.

NCT06247995Breast Cancer

DrugsGa-NeoB·Lu-NeoB·Capecitabine

Novartis Pharmaceuticals

Phase 1/2

Grenoble, Saint-Herblain, Villejuif

2024-08-14

Active, closed

A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms

NCT06313593Myeloproliferative Neoplasms

Incyte Corporation

Phase 1

Paris, Villejuif

2024-08-08

Active, closed

Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)

NCT06162572Non-small Cell Lung Cancer (NSCLC)

DrugsS095029·Cemiplimab

Servier Bio-Innovation LLC

Phase 1/2

102

Dijon, Grenoble, Marseille, Saint-Herblain, Villejuif

2024-08-07

Recruiting

Study of STP938 (Dencatistat) in Advanced Solid Tumours

NCT06297525Solid Tumor

DrugSTP938

Step Pharma, SAS

Phase 1

Villejuif

2024-08-02

Active, closed

A Study of GR1014 Cutaneous Gel for the Prevention of Skin Reactions Caused by Radiation Therapy for Breast Cancer

NCT07192588Radiodermatitis; Acute

Graegis Pharmaceuticals Ltd

Phase 2

273

Bordeaux, Lyon, Villejuif

2024-07-26

Recruiting

A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors

NCT06427941Metastatic Hepatocellular Carcinoma, Local Advanced Hepatocellular Carcinoma, Alpha-fetoprotein (AFP)-Producing Gastric Cancer, Extragonadal Yolk Sac Tumors

DrugsTislelizumab·Bevacizumab

BeOne Medicines

Phase 1/2

630

Clichy, Nantes, Villejuif

2024-07-23

Recruiting

A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)

NCT06362252Extensive Stage-small Cell Lung Cancer

DrugsIfinatamab Deruxtecan·Atezolizumab·Carboplatin

Daiichi Sankyo

Phase 1/2

123

Lille, Lyon, Marseille, Paris, Rennes, Saint-Herblain, Suresnes, Villejuif

2024-07-22

Recruiting

Lymphocyte Support to SBRT in Patients With Oligo-metastatic Solid Cancer

NCT06439888Oligometastatic Disease, Solid Tumor, Adult

DrugsVesanoid·Tretinoin·All-trans retinoic acid

Gustave Roussy, Cancer Campus, Grand Paris

Phase 1/2

Lyon, Villejuif

2024-07-11

Recruiting

VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]

NCT06264180Advanced Melanoma

DrugsVusolimogene Oderparepvec·Relatlimab·Opdivo·Nivolumab

Replimune, Inc.

Phase 3

400

Bordeaux, Lille, Marseille, Nice, Paris, Pierre-Bénite, Villejuif

2024-07-11

Active, closed

Lenvatinib Treatment in Waiting List of Liver Transplantation After TACE Failure in Patients With Hepatocellular Carcinoma

NCT05901194Hepatocellular Carcinoma Non-resectable

DrugLenvatinib

Assistance Publique - Hôpitaux de Paris

Phase 1/2

Bordeaux, Créteil, Lille, Rennes, Tours, Villejuif

2024-07-10

Recruiting

A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negative Breast Cancer

NCT06508216Breast Cancer

DrugsDato-DXd·Durvalumab

Gustave Roussy, Cancer Campus, Grand Paris

Phase 1/2

Villejuif

2024-07-05

Recruiting

Talazoparib Plus Enzalutamide After Progression to Prior ARPi in Metastatic Prostate Cancer

NCT06582628Metastatic Prostate Cancer

DrugEnzalutamide

Fundacion Oncosur

Phase 2

Bordeaux, Brest, Lille, Paris, Strasbourg, Villejuif

2024-07-05

Recruiting

A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1)

NCT06431594Solid Tumors, Neoplasms

DrugMocertatug rezetecan

GlaxoSmithKline

Phase 1

675

Lyon, Saint-Herblain, Villejuif

2024-07-02

Recruiting

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

NCT06465069Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm

DrugPembrolizumab

Eli Lilly and Company

Phase 1

460

Villejuif

2024-07-01

Active, closed

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

NCT06305754Non-small Cell Lung Cancer (NSCLC)

DrugsSteroid mouthwash (dexamethasone·Acetaminophen·Sacituzumab tirumotecan·Pemetrexed

Merck Sharp & Dohme LLC

Phase 3

550

Strasbourg, Marseille, Paris, Villejuif

2024-06-11

Active, closed

Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

NCT06082167Head and Neck Squamous Cell Carcinoma

DrugsZanzalintinib·Keytruda·Pembrolizumab

Exelixis

Phase 2/3

600

Marseille, Bordeaux, Rennes, Saint Priest En Jarez, Lyon, Le Mans, Villejuif, Dijon

2024-06-07

Recruiting

Establishment of a Biobank for the Evaluation of Rapid Diagnostic Solutions

NCT07411729Emerging Infectious Diseases, Communicable Diseases, Biological Warfare Agents, Zoonoses

Assistance Publique - Hôpitaux de Paris

Observational

800

Le Kremlin-Bicêtre, Villejuif

2024-06-03

Active, closed

A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)

NCT06360354Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers

DrugsAnvumetostat·Modified FOLFIRINOX·Cetuximab·Nab-paclitaxel

Amgen

Phase 1

120

Bordeaux, Dijon, Marseille, Villejuif

2024-05-29

Recruiting

Alteration of Symbiosis Intestinal Microbiota on Patients With Anorexia Nervosa

NCT05632497Anorexia Nervosa, Dysbiosis, Anxious Depression

Assistance Publique - Hôpitaux de Paris

Observational

120

Villejuif

2024-05-23

Active, closed

Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)

NCT06353386Prostatic Neoplasms, Castration-Resistant

DrugsFludrocortisone acetate·Opevesostat·Cabazitaxel·Taxotere

Merck Sharp & Dohme LLC

Phase 1/2

220

Bordeaux, Strasbourg, Paris, Villejuif

2024-05-20

Active, closed

A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)

NCT06346067Advanced or Metastatic NRAS-mutant Melanoma

DrugsNaporafenib·Temodar·Dacarbazine·Trametinib

Erasca, Inc.

Phase 3

Bordeaux, Dijon, Le Mans, Lille, Lyon, Marseille, Paris, Villejuif

2024-04-29

Recruiting

Study of REM-422 in Patients With AML or Higher Risk MDS

NCT06297941Myelodysplastic Syndromes, Higher Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, Acute Myeloid Leukemia Refractory

DrugREM-422

Remix Therapeutics

Phase 1

100

Bordeaux, Paris, Toulouse, Villejuif

2024-04-26

Recruiting

A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer

NCT06385080Squamous Cell Carcinoma of Head and Neck

DrugsAmivantamab·Paraplatin·Taxol·Keytruda

Janssen Research & Development, LLC

Phase 1/2

287

Avignon, Lille, Nantes, Paris, Villejuif

2024-04-22

Recruiting

A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors

NCT06311578Neoplasms

DrugCetrelimab

Johnson & Johnson Enterprise Innovation Inc.

Phase 1

126

Villejuif

2024-04-10

Recruiting

A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

NCT06330064Recurrent or Metastatic Solid Tumors

DrugIfinatamab Deruxtecan

Daiichi Sankyo

Phase 1/2

680

Dijon, Bordeaux, Montpellier, Rennes, Saint-Herblain, Paris, Lyon, Villejuif

2024-04-10

Active, closed

A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).

NCT06307431Renal Cell Carcinoma

DrugsIntismeran autogene·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 2

272

Lyon Cedex08, Besançon, Toulouse, Paris, Villejuif

2024-04-10

Active, closed

A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours

NCT06305247Melanoma, Head and Neck Squamous Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer

Ipsen

Phase 1/2

Lyon, Paris, Saint-Herblain, Villejuif

2024-04-03

Recruiting

A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors

NCT06265727Solid Tumor, Adult

DrugsCRB-701·Anti-PD-1

Corbus Pharmaceuticals Inc.

Phase 1/2

348

Montpellier, Poitiers, Saint-Herblain, Villejuif

2024-04-01

Active, closed

A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)

NCT06305767Bladder Cancer

DrugsIntismeran autogene·Enfortumab Vedotin·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 1/2

230

Toulouse, Angers, Lille, Paris, Villejuif

2024-03-28

Recruiting

Evaluation Contact X-ray Brachytherapy for Rectal Preservation in Intermediate Substage Rectal Adenocarcinoma

NCT06402864Adult With Intermediate Low or Mid Rectal Adenocarcinoma

Gustave Roussy, Cancer Campus, Grand Paris

Phase 3

212

Avignon, Lyon, Marseille, Mâcon, Nice, Saint-Etienne, Saint-Herblain, Villejuif

2024-03-26

Recruiting

Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd

NCT06298084Breast Cancer Metastatic, HER2-positive Metastatic Breast Cancer, HER2 Low Breast Carcinoma, Advanced Breast Cancer

DrugsPatritumab deruxtecan·Olaparib

Gustave Roussy, Cancer Campus, Grand Paris

Phase 1/2

152

Villejuif

2024-03-21

Active, closed

A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer

NCT06318273Metastatic Castration-Resistant Prostate Cancer

AbbVie

Phase 1

152

Lille, Lyon, Villejuif

2024-03-08

Active, closed

A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors

NCT06238479Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm

Eli Lilly and Company

Phase 1

490

Lille, Lyon, Marseille, Strasbourg, Villejuif

2024-03-05

Active, closed

BioPearl™ Microspheres Loaded With Doxorubicin for the Treatment of Unresectable Hepatocellular Carcinoma (HCC)

NCT05911633Hepatocellular Carcinoma Non-resectable

Terumo Europe N.V.

Not applicable

Clichy, La Tronche, Villejuif

2024-02-27

Active, closed

First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer

NCT06239467Advanced Cancer, Breast Cancer, Advanced Solid Tumors, PI3K Gene Mutation

DrugsAtirmociclib·Tucatinib·Ribociclib·Fulvestrant

OnKure, Inc.

Phase 1

200

Dijon, Lille, Lyon, Nice, Pierre-Bénite, Villejuif

2024-02-26

Recruiting

SNV1521 in Participants With Advanced Solid Tumors

NCT06220864Advanced Solid Tumor

DrugsDB-1310·SNV1521·Abiraterone·Darolutamide

ParVation Therapeutics, Inc.

Phase 1

400

Bordeaux, Lyon, Villejuif

2024-02-23

Active, closed

DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer

NCT06077500Small Cell Lung Carcinoma (SCLC)

DrugsObrixtamig·Etoposide·Atezolizumab·Carboplatin

Boehringer Ingelheim

Phase 1

Bordeaux, Bron, Strasbourg, Villejuif

2024-02-14

Active, closed

DAREON™-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With a Single Agent Chemotherapy

NCT05990738Small Cell Lung Carcinoma (SCLC)

DrugsObrixtamig·Topotecan

Boehringer Ingelheim

Phase 1

Paris, Strasbourg, Villejuif

2024-02-14

Active, closed

Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

NCT06151574Lung Cancer, Non-squamous, Non-small Cell

DrugsZongertinib·Pemetrexed·Keytruda·Cisplatin

Boehringer Ingelheim

Phase 3

428

Bron, Lyon, Marseille, Paris, Rennes, Strasbourg, Toulouse, Villejuif

2024-02-09

Recruiting

A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors

NCT06004245Advanced Solid Tumors, Colorectal Cancer

DrugsVVD-133214·Avastin·Keytruda·Bevacizumab

Vividion Therapeutics, Inc.

Phase 1

280

Lyon, Montpellier, Paris, Toulouse, Villejuif

2024-01-25

Active, closed

Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)

NCT06225596Metastatic Urothelial Cancer

DrugsZelenectide pevedotin·Avelumab·Gemcitabine·Cisplatin

BicycleTx Limited

Phase 2

375

Besançon, Bordeaux, Le Mans, Pierre-Bénite, Villejuif

2024-01-24

Active, closed

A Study of Continued Treatment With Regorafenib in Participants With Solid Tumors Who Have Participated in Other Bayer Studies

NCT06246643Solid Malignant Tumors

DrugRegorafenib

Bayer

Phase 2

Lille, Clichy, Villejuif

2024-01-24

Recruiting

AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.

NCT06137144Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Peripheral T-cell Lymphoma (PTCL)

DrugsAZD3470·Keytruda·Pembrolizumab

AstraZeneca

Phase 1/2

161

Créteil, Dijon, Lille, Pierre-Bénite, Villejuif

2024-01-23

Recruiting

Multicentre Randomised Study Comparing a Taurolidine Lock and a Standard Saline Lock in Paediatric Oncology

NCT05781295Children, Medical Device, Primary Prevention, Oncology

Institut Curie

Not applicable

148

Paris, Villejuif

2024-01-19

Recruiting

A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors

NCT06130553Advanced Solid Tumors That Are MTAP Deficient

DrugsAZD3470·Dato-DXd

AstraZeneca

Phase 1/2

334

Villejuif

2024-01-18

Recruiting

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

NCT06064877Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma

DrugsErbitux·Cetuximab

AVEO Pharmaceuticals, Inc.

Phase 3

410

Brest, Chambray-lès-Tours, Lyon, Marseille, Paris, Plérin, Villejuif

2024-01-11

Recruiting

PROACT is a Prospective Master Protocol for a Cohort Study Focused on Evaluating the Implementation of Integrated Proactive Supportive Care Pathways at Gustave Roussy

NCT06479057Any Cancer

Gustave Roussy, Cancer Campus, Grand Paris

Observational

700

Villejuif

2024-01-11

Active, closed

A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)

NCT06109272Hepatocellular Carcinoma

DrugsLivmoniplimab·Budigalimab·Tremelimumab·Atezolizumab

AbbVie

Phase 2/3

La Tronche, Villejuif, Bobigny, Clichy

2024-01-11

Recruiting

A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)

NCT06174987Advanced Cancer, Metastatic Cancer

DrugTrastuzumab deruxtecan

Daiichi Sankyo

Phase 3

Lille, Marseille, Toulouse, Villejuif

2024-01-05

Recruiting

A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

NCT06179160Solid Tumors

DrugsGEMNabP·INCA33890·INCB161734·Retifanlimab

Incyte Corporation

Phase 1

710

Lyon, Toulouse, Villejuif

2024-01-04

Recruiting

Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer

NCT06190899mCRPC (Metastatic Castration-resistant Prostate Cancer), Genital Diseases, Male, Urogenital Diseases, Male, Prostatic Disease

DrugsGedatolisib·Darolutamide

Celcuity Inc

Phase 1/2

Clermont-Ferrand, Marseille, Nice, Villejuif

2024-01-01

Recruiting

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

NCT06136624Prostate Cancer Metastatic

DrugsFludrocortisone acetate·Opevesostat·Zytiga·Hydrocortisone

Merck Sharp & Dohme LLC

Phase 3

1,310

Lille, Strasbourg, Nîmes, Rennes, Clermont-Ferrand, Bayonne, Villejuif, Paris

2023-12-31

Recruiting

A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas

NCT06090539Relapsed/Refractory Non-Hodgkin Lymphoma

DrugsGolcadomide·Mosunetuzumab·Epcoritamab·Truxima

Bristol-Myers Squibb

Phase 1/2

460

Bordeaux, Lyon, Lille, Villejuif, Créteil, Montpellier, Paris, Toulouse

2023-12-29

Recruiting

Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma

NCT06118086Adenoid Cystic Carcinoma, Metastatic Adenoid Cystic Carcinoma, Recurrent Adenoid Cystic Carcinoma

DrugREM-422

Remix Therapeutics

Phase 1/2

125

Nice, Villejuif

2023-12-20

Active, closed

Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma

NCT05948475Cholangiocarcinoma

DrugTinengotinib

TransThera Sciences (Nanjing), Inc.

Phase 3

200

Avignon, Besançon, Clichy, Levallois-Perret, Lyon, Montpellier, Paris, Villejuif

2023-12-20

Recruiting

Preoperative Radiotherapy And ASTX660 in Rectum Cancer

NCT05912075Locally-advanced Rectal Cancer

DrugsTolinapant·FOLFOX4·MFOLFIRINOX·Folfox

Gustave Roussy, Cancer Campus, Grand Paris

Phase 1

Lyon, Villejuif

2023-12-19

Recruiting

A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment

NCT05828511Multiple Myeloma

DrugLinvoseltamab

Regeneron Pharmaceuticals

Phase 1/2

149

Poitiers, Lille, Montpellier, Paris, Antony, Villejuif

2023-12-19

Active, closed

REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)

NCT05973773Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation

DrugZipalertinib

Taiho Oncology, Inc.

Phase 3

285

Strasbourg, Caen, Limoges, Pessac, Le Mans, Villejuif, Quimper, Boulogne-Billancourt

2023-12-18

Recruiting

A Study of JNJ-87890387 for Advanced Solid Tumors

NCT06178614Neoplasms, Advanced Solid Tumors

Janssen Research & Development, LLC

Phase 1

200

Lyon, Villejuif

2023-12-14

Recruiting

A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy

NCT06129864Locally Advanced Head and Neck Squamous Cell Carcinoma

DrugVolrustomig

AstraZeneca

Phase 3

1,145

Avignon, Bordeaux, Le Mans, Lyon, Nice, Saint-Herblain, Toulouse, Villejuif

2023-12-14

Active, closed

A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib

NCT05734105GIST

DrugsRipretinib·Sunitinib

Deciphera Pharmaceuticals, LLC

Phase 3

Dijon, Rennes, Bordeaux, Lyon, Villejuif

2023-12-13

Recruiting

A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors

NCT06253130Advanced Solid Tumor

Eikon Therapeutics

Phase 1/2

156

Pierre-Bénite, Caen, Villejuif

2023-12-11

Active, closed

Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

NCT06109779Biliary Tract Cancer

DrugsGemcitabine/Cisplatin·Rilvegostomig·Teysuno·Capecitabine

AstraZeneca

Phase 3

760

Marseille, Montpellier, Pessac, Rennes, Strasbourg, Toulouse, Villejuif

2023-12-04

Recruiting

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

NCT06120283Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer

DrugsBGB-43395·Elacestrant·Letrozole·Fulvestrant

BeOne Medicines

Phase 1

433

Bordeaux, Caen, Lille, Marseille, Paris, Rennes, Saint-Herblain, Villejuif

2023-12-01

Recruiting

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

NCT06103864Breast Cancer

DrugsDato-DXd·Durvalumab·Nab-paclitaxel·Gemcitabine

AstraZeneca

Phase 3

625

Lille, Lyon, Montpellier, Paris, Saint-Herblain, Toulouse, Vandœuvre-lès-Nancy, Villejuif

2023-11-23

Recruiting

A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors

NCT06131840Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Pancreatic Ductal Adenocarcinoma

DrugsLeucovorin·Adrucil·Oxaliplatin·Bevacizumab

Seagen, a wholly owned subsidiary of Pfizer

Phase 1

914

Villejuif

2023-11-20

Active, closed

OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

NCT06016738Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer

DrugsPalazestrant·Exemestane·Anastrozole·Letrozole

Olema Pharmaceuticals, Inc.

Phase 3

510

Bourg-en-Bresse, Besançon, Nantes, Compiègne, Clermont-Ferrand, Le Mans, Villejuif, Caen

2023-11-16

Active, closed

A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202

NCT06062420Neoplasms, Head and Neck

DrugsRemzistotug·Nelistotug·Belrestotug·Dostarlimab

GlaxoSmithKline

Phase 2

316

Bordeaux, Caen, Marseille, Paris, Rouen, Villejuif

2023-11-14

Recruiting

A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma

NCT05583617Multiple Myeloma

DrugsCevostamab·Iberdomide·Tocilizumab·Lenalidomide

Hoffmann-La Roche

Phase 1/2

200

Pierre-Bénite, Toulouse, Tours, Villejuif

2023-11-14

Recruiting

Analyzing and Solving Exceptional Long-term Survivors in Solid Tumors With Poor Prognosis

NCT06160596Pancreas Adenocarcinoma, Small-cell Lung Cancer, Glioblastoma, IDH-wildtype

Cure 51

Observational

1,020

Villejuif

2023-11-01

Recruiting

A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer

NCT06095089Prostatic Neoplasms

DrugsJNJ-101556143·JNJ-87189401·Lutetium Lu 177 vipivotide tetraxetan·Pasritamig

Janssen Research & Development, LLC

Phase 1

355

Bordeaux, Lyon, Villejuif

2023-11-01

Recruiting

A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours

NCT06725758Solid Tumours

DrugODM-212

Orion Corporation, Orion Pharma

Phase 1/2

315

Bordeaux, Lille, Villejuif

2023-10-26

Active, closed

ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions

NCT05949684Myelodysplastic Syndromes

DrugsEpoetin Alfa·Reblozyl·Luspatercept

Bristol-Myers Squibb

Phase 3

402

Nice, Pessac, Tours, La Tronche, Vandœuvre-lès-Nancy, Angers, Villejuif, Paris

2023-10-24

Active, closed

A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC

NCT05968326Adenocarcinoma, Pancreatic Ductal

DrugsAutogene Cevumeran·MFOLFIRINOX·Tecentriq·Atezolizumab

Genentech, Inc.

Phase 2

260

Lille, Lyon, Marseille, Vandœuvre-lès-Nancy, Villejuif

2023-10-18

Recruiting

A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer

NCT06067841Metastatic Castration-resistant Prostate Cancer

Bristol-Myers Squibb

Phase 1

140

Bordeaux, Lyon Cedex08, Marseille, Villejuif, Paris

2023-10-18

Active, closed

A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation

NCT06045806Multiple Myeloma

DrugsIdecabtagene vicleucel·Endoxan·Fludara·Cytoxan

Celgene

Phase 3

Pessac, Marseille, Lille, Nantes, Pierre-Bénite, Créteil, Villejuif, Poitiers

2023-10-16

Active, closed

Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast Cancer

NCT05552001Triple Negative Breast Cancer, Metastatic Breast Cancer

DrugSacituzumab Govitecan

UNICANCER

Phase 3

Villejuif

2023-10-05

Recruiting

First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations

NCT06043817Non-Small Cell Lung Cancer, NSCLC, EGFR/HER2 Exon 20 Insertion Mutation

Pierre Fabre Medicament

Phase 1/2

345

Saint-Herblain, Bordeaux, Lille, Lyon, Marseille, Toulouse, Villejuif

2023-09-26

Active, closed

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

NCT05936359Myeloproliferative Neoplasms

DrugsINCA033989·Ruxolitinib

Incyte Corporation

Phase 1

160

Bordeaux, Nîmes, Paris, Villejuif

2023-09-25

Active, closed

Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

NCT05911295Urothelial Carcinoma

DrugsDisitamab Vedotin·Keytruda·Gemcitabine·Cisplatin

Seagen, a wholly owned subsidiary of Pfizer

Phase 3

412

Pierre-Bénite, Bordeaux, Strasbourg, Villejuif

2023-09-22

Active, closed

Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)

NCT05822752Hepatocellular Carcinoma

DrugsLivmoniplimab·Budigalimab·Sorafenib·Lenvatinib

AbbVie

Phase 2

130

Pessac, Montpellier, La Tronche, Lille, Villejuif, Clichy

2023-09-21

Recruiting

A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma

NCT05730036Relapsed Refractory Multiple Myeloma (RRMM)

DrugsElotuzumab·Linvoseltamab·Pomalidomide·Dexamethasone

Regeneron Pharmaceuticals

Phase 3

410

Lyon, Pessac, Lille, Paris, Saint-Cloud, Villejuif

2023-09-18

Recruiting

Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis

NCT06051617Primary Biliary Cholangitis

DrugSeladelpar

Gilead Sciences

Phase 3

402

Bobigny, Lille, Lyon, Montipellier, Paris, Strasbourg, Vandœuvre-lès-Nancy, Villejuif

2023-09-07

Not yet open

Resection And Partial LIver Transplantation With Delayed Hepatectomy for Hepatocellular Carcinoma

NCT05971628Hepatocellular Carcinoma

Assistance Publique - Hôpitaux de Paris

Not applicable

Villejuif

2023-09

Active, closed

A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC

NCT05884398Metastatic Castrate-sensitive Prostate Cancer

DrugApalutamide

Janssen Research & Development, LLC

Phase 3

420

Bordeaux, Lyon, Paris, Rennes, Villejuif

2023-08-31

Recruiting

First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors

NCT05875168Advanced Solid Tumor, Metastatic Solid Tumor

DrugDS-3939a

Daiichi Sankyo

Phase 1/2

590

Lyon, Marseille, Saint-Herblain, Strasbourg, Toulouse, Villejuif

2023-08-18

Active, closed

Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)

NCT05771480Biliary Tract Cancer

DrugsAlbumin-Bound Paclitaxel·Teysuno·Durvalumab·Oxaliplatin

AstraZeneca

Phase 3

142

Clichy, Dijon, Montpellier, Villejuif

2023-08-16

Recruiting

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

NCT05983432Non Small Cell Lung Cancer, Esophageal Cancer, Small Cell Lung Cancer, Nasopharyngeal Cancer

DrugIza-bren

SystImmune Inc.

Phase 1

540

Lyon, Paris, Saint-Herblain, Villejuif

2023-08-08

Recruiting

Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma

NCT05287945Carcinoma, Renal Cell

Oncorena AB

Phase 1/2

Villejuif

2023-08-04

Recruiting

PREventing Second Cancers With DOSTARlimab

NCT05855811Recurrent Cancer, Primary Cancer, Second Cancer

DrugDostarlimab

Centre Leon Berard

Phase 2

400

Caen, Clermont-Ferrand, Lyon, Toulouse, Villejuif

2023-07-26

Recruiting

A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

NCT05836324Solid Tumors, Advanced Solid Tumors, Metastatic Solid Tumors

DrugsINCA33890·ADG126·Folfox·Cetuximab

Incyte Corporation

Phase 1

570

Lyon, Villejuif

2023-07-24

Recruiting

Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors

NCT06005493Gastric Cancer, Gastro-esophageal Junction Cancer, Pancreatic Ductal Adenocarcinoma, Esophageal Adenocarcinoma

DrugRilvegostomig

AstraZeneca

Phase 1/2

392

Toulouse, Villejuif

2023-07-11

Active, closed

Casting Light on HOst-cytomegaloviRUs Interaction in Solid Organ Transplantation

NCT05701228Cytomegalovirus Infections, Solid Organ Transplantation

University Hospital, Bordeaux

Observational

552

Bordeaux, Lyon, Paris, Suresnes, Toulouse, Villejuif

2023-06-26

Active, closed

Phase Ib / Regorafenib With Conventional Chemotherapy/Newly Diagnosed Patients/ Multimetastatic Ewing Sarcoma

NCT05830084Ewing Sarcoma

DrugRegorafenib

Gustave Roussy, Cancer Campus, Grand Paris

Phase 1

Bordeaux, Lille, Lyon, Paris, Villejuif

2023-06-16

Active, closed

Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies

NCT05753501Hematologic Cancer

DrugVenetoclax

AbbVie

Phase 1

135

Bordeaux, Montpellier, Lille, Nantes, Villejuif, Paris

2023-06-09

Active, closed

A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors

NCT05888831Advanced Solid Tumors

DrugsOpdivo·Nivolumab

Bristol-Myers Squibb

Phase 1/2

100

Villejuif, Marseille, Bordeaux

2023-06-06

Active, closed

Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)

NCT05607550Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer, EGFR Exon 20 Mutations

DrugFurmonertinib

ArriVent BioPharma, Inc.

Phase 3

398

Caen, Lyon, Marseille, Toulouse, Villejuif

2023-06-01

Recruiting

Morbidity, Long-term Side Effects and Quality of Life in Germ-cell Tumor Long Survivors Treated with High-dose Chemotherapy and Autologous Stem Cell Transplant

NCT05889585Germ Cell Tumor

Gustave Roussy, Cancer Campus, Grand Paris

Not applicable

180

Villejuif

2023-05-31

Recruiting

Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

NCT05732831Locally Advanced Solid Tumor

DrugsTNG462·Keytruda·Pembrolizumab

Tango Therapeutics, Inc.

Phase 1/2

225

Brest, Lyon, Saint-Herblain, Villejuif

2023-05-26

Active, closed

EMITT-1 (ERAP Mediated Immunopeptidome Targeting Trial - 1)

NCT06923761Advanced Solid Malignancy

Grey Wolf Therapeutics

Phase 1/2

300

Lyon, Marseille, Rennes, Saint-Herblain, Strasbourg, Toulouse, Villejuif

2023-05-21

Recruiting

Engineering Immune Organoids to Study Pediatric Cancer

NCT05890781Brain Tumor, Kidney Tumor, Neuroblastoma, Sarcoma

DrugBlood sample

Gustave Roussy, Cancer Campus, Grand Paris

Not applicable

108

Villejuif, Paris

2023-05-12

Active, closed

Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO) (ROSY-T)

NCT05629234Cancer

DrugsTagrisso·Osimertinib

AstraZeneca

Phase 3

Villejuif

2023-05-08

Recruiting

Validation of a Treatment Algorithm for Poor-Risk NSGCTnon Seminomatous Germ-cell Tumors

NCT05705687Non-Seminomatous Germ Cell Tumor

Gustave Roussy, Cancer Campus, Grand Paris

Not applicable

150

Villejuif

2023-05-05

Active, closed

Phase III Study of AK112 for NSCLC Patients

NCT06396065Non-Squamous Non-small Cell Lung Cancer

DrugsIvonescimab·Pemetrexed·Carboplatin

Summit Therapeutics

Phase 3

420

Créteil, Lyon, Paris, Villejuif

2023-05-04

Recruiting

A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer

NCT05800665Advanced Prostate Cancer, Metastatic Prostate Cancer

Genentech, Inc.

Phase 1

210

Villejuif, Lyon, Marseille

2023-05-02

Active, closed

A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

NCT05805501Renal Cell Carcinoma

DrugsTobemstomig·Tiragolumab·Axitinib·Keytruda

Hoffmann-La Roche

Phase 2

199

Avignon, Besançon, Bordeaux, Caen, Lyon, Villejuif

2023-04-21

Recruiting

A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas

NCT05685173B-cell Non-Hodgkins Lymphoma (B-NHL)

DrugOdronextamab

Regeneron Pharmaceuticals

Phase 1

107

Talence, Paris, Villejuif

2023-04-20

Recruiting

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

NCT05786924Non-small Cell Lung Cancer, Histiocytic Neoplasm, Histiocytosis, BRAF Gene Mutation

DrugsPanitumumab·Folfox·Cetuximab·Nab-paclitaxel

Institut de Recherches Internationales Servier

Phase 1/2

554

Dijon, Paris, Rennes, Villejuif

2023-04-18

Recruiting

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

NCT05768139Breast Cancer, Solid Tumors, Adult

DrugsTersolisib·Imlunestrant·Tamoxifen·Exemestane

Eli Lilly and Company

Phase 1/2

880

Bordeaux, Lyon, Marseille, Nice, Toulouse, Villejuif

2023-04-17

Active, closed

A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer

NCT05645692Urothelial Cancer

DrugsTobemstomig·Tiragolumab·Atezolizumab

Hoffmann-La Roche

Phase 2

204

Lyon, Villejuif

2023-04-13

Recruiting

Study of SGR-1505 in Mature B-Cell Neoplasms

NCT05544019Mature B-Cell Neoplasm, Non Hodgkin Lymphoma, DLBCL, Waldenstrom Macroglobulinemia

Schrödinger, Inc.

Phase 1

Créteil, Villejuif

2023-04-10

Active, closed

ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer

NCT05650879HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation, HER2 Amplification

DrugsELVN-002·Fam-Trastuzumab Deruxtecan-Nxki·Trastuzumab emtansine·Trastuzumab deruxtecan

Enliven Therapeutics

Phase 1

198

Marseille, Rennes, Caen, Bordeaux, Dijon, Lyon, Villejuif

2023-03-20

Recruiting

Mechanism of Action of Interferon in the Treatment of Myeloproliferative Neoplasms

NCT05850273Myeloproliferative Neoplasm

Institut National de la Santé Et de la Recherche Médicale, France

Observational

Villejuif

2023-03-16

Not yet open

Improve MRI Diagnosis

NCT05744102New MRI Techniques

Assistance Publique - Hôpitaux de Paris

Not applicable

2,016

Villejuif

2023-03-15

Recruiting

Erdafitinib Monotherapy or in Combination With Cetrelimab in Muscle-invasive Bladder Cancer Patients With Fibroblast Growth Factor Receptor (FGFR ) Gene Alterations

NCT06511648Muscle-invasive Bladder Cancer

DrugErdafitinib

Spanish Oncology Genito-Urinary Group

Phase 2

Clermont-Ferrand, Lyon, Paris, Toulouse, Villejuif

2023-03-07

Active, closed

A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma

NCT05625399Melanoma

DrugsPhesgo·Relatlimab·Nivolumab

Bristol-Myers Squibb

Phase 3

579

Toulouse, Chambray-lès-Tours, Lille, Nantes, Villejuif, Amiens, Bayonne, Bordeaux

2023-03-06

Active, closed

DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

NCT05566795Low-grade Glioma, Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma, Pediatric Low-grade Glioma

DrugsTovorafenib·Carboplatin

Day One Biopharmaceuticals, Inc.

Phase 3

418

Lille, Lyon, Marseille, Paris, Villejuif

2023-02-27

Recruiting

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

NCT05503797Cancer Harboring BRAF Alterations, HGG, LGG, Solid Tumors

DrugPlixorafenib

Fore Biotherapeutics

Phase 2

254

Bordeaux, Marseille, Brest, Angers, Villejuif, Toulouse, Paris

2023-02-21

Recruiting

Safety Study of the Repeated Opening of the Blood-brain Barrier With the SonoCloud® Device to Treat Malignant Brain Tumors in Pediatric Patients

NCT05293197Malignant Brain Tumor, Malignant Glioma, Embryonal Tumor

Assistance Publique - Hôpitaux de Paris

Phase 1

Paris, Villejuif

2023-02-06

Active, closed

Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer

NCT05563220Breast Cancer, Metastatic Breast Cancer

DrugsAlpelisib·Capivasertib·Elacestrant·Everolimus

Stemline Therapeutics, Inc.

Phase 1/2

435

Lyon, Montpellier, Rouen, Toulouse, Villejuif

2023-01-24

Recruiting

FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3

NCT05614739Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral Neoplasms

DrugsVepugratinib·Digoxin·Enfortumab Vedotin·Rosuvastatin

Eli Lilly and Company

Phase 1

677

Bordeaux, Lyon, Villejuif

2023-01-12

Active, closed

First in Human Study of IMGN151 in Recurrent Gynaecological Cancers

NCT05527184Endometrial Cancer, High Grade Serous Adenocarcinoma of Ovary, Primary Peritoneal Carcinoma, Fallopian Tube Cancer

DrugIMGN151

AbbVie

Phase 1

256

Saint-Herblain, Nice, Lyon, Pierre-Bénite, Villejuif

2023-01-11

Recruiting

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

NCT05592626Advanced Solid Tumors, Genital Neoplasm, Female, Urogenital Neoplasms, Lung Neoplasm

DrugSTAR0602

Marengo Therapeutics, Inc.

Phase 1/2

366

Villejuif

2023-01-04

Recruiting

Hepatic and Systemic Hemodynamic Modeling During Liver Surgery

NCT05339984Liver Diseases, Liver Transplantation

Assistance Publique - Hôpitaux de Paris

Not applicable

150

Villejuif

2023-01-03

Active, closed

First in Human Study of AZD9592 in Solid Tumors

NCT05647122Advanced Solid Tumours, Carcinoma Non-small Cell Lung, Head and Neck Neoplasms, Colorectal Neoplasms

DrugsAZD9592·Osimertinib·Leucovorin·Adrucil

AstraZeneca

Phase 1

190

Marseille, Rennes, Villejuif

2022-12-21

Recruiting

Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas

NCT05751798Solid Advanced Tumor, Lymphoma, NSCLC (Non-small Cell Lung Cancer)

OSE Immunotherapeutics

Phase 1/2

Lyon, Paris, Rennes, Saint-Herblain, Toulouse, Villejuif

2022-12-20

Recruiting

Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours

NCT05752552Adult Solid Tumor, Advanced Solid Tumor, Refractory Tumor, Non-small Cell Lung Cancer

DeuterOncology

Phase 1

Bordeaux, Lille, Lyon, Marseille, Nice, Rennes, Villejuif

2022-12-20

Recruiting

Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

NCT05549297Advanced Melanoma

DrugTebentafusp

Immunocore Ltd

Phase 3

540

Lyon, Toulouse, Villejuif, Bordeaux, Marseille, Paris

2022-12-19

Recruiting

Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER

NCT05640999Endometrial Cancer

Canadian Cancer Trials Group

Phase 2

393

Lyon, Villejuif, Lille, Toulouse, Paris

2022-12-19

Active, closed

A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)

NCT05469737Myelodysplastic Syndromes

DrugsOnureg·Azacitidine

Bristol-Myers Squibb

Phase 2/3

230

Pessac, Tours, Angers, Lille, Villejuif, Paris

2022-12-14

Recruiting

Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With Mutated KRAS p.G12C

NCT05631249KRAS P.G12C, Non Small Cell Lung Cancer

Gustave Roussy, Cancer Campus, Grand Paris

Phase 2

Lyon, Marseille, Paris, Villejuif

2022-12-13

Active, closed

Personalized First-line Chemotherapy Choice in Advanced Pancreatic Adenocarcinoma Using Transcriptomic Signatures

NCT05475366Carcinoma, Pancreatic Ductal, Prognosis

Institut Curie

Not applicable

Clichy, Créteil, Lille, Marseille, Reims, Saint-Cloud, Villejuif

2022-12-12

Active, closed

Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)

NCT05501886Breast Cancer

DrugsGedatolisib·Alpelisib·Palbociclib·Fulvestrant

Celcuity Inc

Phase 3

701

Bordeaux, Caen, La Roche-sur-Yon, Marseille, Poitiers, Strasbourg, Villejuif

2022-12-08

Recruiting

Opioid Free Versus Opioid Based Anaesthesia for Free Flap Reconstruction Surgery of the Breast: A Phase III Multicentric Randomized Controlled Study.

NCT05439005Breast Cancer

DrugDexmedetomidine

Institut Curie

Phase 3

158

Paris, Saint-Cloud, Villejuif

2022-12-07

Active, closed

Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors

NCT05599984Advanced Solid Tumors

DrugsABBV-706·Budigalimab·Cisplatin·Carboplatin

AbbVie

Phase 1

288

Bordeaux, Villejuif, Montpellier

2022-12-05

Active, closed

A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer

NCT05608044Metastatic Colorectal Cancer

DrugsBalstilimab·Botensilimab

Agenus Inc.

Phase 2

234

Besançon, Marseille, Paris, Poitiers, Villejuif

2022-11-30

Active, closed

Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS

NCT05688280Metastatic Solid Tumor, Colon Cancer, Nonsmall Cell Lung Cancer, Soft Tissue Sarcoma

DrugIP-001

Immunophotonics, Inc.

Phase 1/2

Bordeaux, Paris, Suresnes, Villejuif

2022-11-29

Active, closed

Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations

NCT05544552Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Solid Tumor, Urothelial Carcinoma

DrugTYRA-300

Tyra Biosciences, Inc

Phase 1/2

310

Saint-Herblain, Toulouse, Villejuif

2022-11-22

Recruiting

A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma

NCT05533775Mature B-Cell Non-Hodgkin Lymphoma

DrugsIfosfamide·Glofitamab·Tocilizumab·Obinutuzumab

Hoffmann-La Roche

Phase 1/2

Bordeaux, Villejuif

2022-11-16

Recruiting

A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

NCT05498428Carcinoma, Non-small-Cell Lung

DrugsDirect Anticoagulant·LMWH·DOAC·Low molecular weight heparin

Janssen Research & Development, LLC

Phase 2

520

Caen, Dijon, Nîmes, Paris, Saint-Herblain, Villejuif

2022-11-11

Recruiting

A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant

NCT05623020Multiple Myeloma

DrugsElranatamab·Bortezomib·Daratumumab·Lenalidomide

Pfizer

Phase 3

1,060

Nice, Toulouse, Poitiers, Nantes, Paris, Tours, Villejuif

2022-11-10

Recruiting

A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

NCT05208762Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Esophageal Squamous Cell Carcinoma, Triple Negative Breast Neoplasms

DrugsPF-08046054·Keytruda·Pembrolizumab

Seagen, a wholly owned subsidiary of Pfizer

Phase 1

714

Bordeaux, Neuilly-sur-Seine, Paris, Villejuif

2022-10-25

Recruiting

Deescalation of Endocrine Therapy Duration in Women With HR+ HER2- Breast Cancer at Very Low Risk

NCT05297617Breast Cancer

UNICANCER

Phase 2

696

Limoges, Villejuif

2022-10-12

Active, closed

A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors

NCT05537740Advanced Solid Tumors

DrugPembrolizumab

Bayer

Phase 1

129

Lille, Bordeaux, Saint-Herblain, Villejuif

2022-10-11

Active, closed

Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab

NCT05206357Non-hodgkin Lymphoma

DrugEpcoritamab

Genmab

Phase 1

Bordeaux, Nantes, Villejuif, Lyon

2022-10-04

Recruiting

Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0

NCT05476939Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Diffuse Midline Glioma, H3K27-altered

DrugsDordaviprone·Everolimus

Gustave Roussy, Cancer Campus, Grand Paris

Phase 3

433

Villejuif, Amiens, Angers, Besançon, Bordeaux, Brest, Caen, Clermont-Ferrand

2022-09-29

Active, closed

Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMM

NCT07150104Multiple Myeloma

DrugsNirogacestat·Belantamab mafodotin·Pomalidomide·Dexamethasone

GlaxoSmithKline

Phase 1/2

Villejuif

2022-08-31

Recruiting

A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma

NCT05548296Endometrial Adenocarcinoma

DrugGemcitabine

Acrivon Therapeutics

Phase 2

350

Caen, Lyon, Saint-Herblain, Villejuif

2022-08-29

Active, closed

First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

NCT05361395Extensive Stage Small Cell Lung Cancer

DrugsTarlatamab·Tecentriq·Etoposide·Atezolizumab

Amgen

Phase 1

184

Lyon, Saint-Herblain, Villejuif

2022-08-24

Recruiting

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

NCT05137054Multiple Myeloma

DrugsNirogacestat·Cevostamab·Fianlimab·Linvoseltamab

Regeneron Pharmaceuticals

Phase 1

317

Poitiers, Lille, Nantes, Angers, Montpellier, Paris, Villejuif, Créteil

2022-08-17

Recruiting

A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation

NCT05410145KRAS P.G12C

DrugsD3S-001·Cetuximab·Pemetrexed·Cisplatin

D3 Bio (Wuxi) Co., Ltd

Phase 1/2

442

Bordeaux, Lyon, Rennes, Villejuif

2022-08-03

Recruiting

A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas

NCT05463263Lymphoma, B-Cell, Lymphoma, T-Cell

DrugSTP938

Step Pharma, SAS

Phase 1/2

180

Paris, Lyon, Marseille, Nantes, Villejuif

2022-08-03

Active, closed

First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors

NCT05489237Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumor (GIST), Digestive System Disease, Gastrointestinal Diseases

DrugIDRX-42

IDRX, Inc., a wholly owned subsidiary of GSK, LLC

Phase 1

276

Bordeaux, Lyon, Marseille, Villejuif

2022-08-03

Active, closed

Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM

NCT07150091Multiple Myeloma

DrugsNirogacestat·Belantamab mafodotin·Lenalidomide·Dexamethasone

GlaxoSmithKline

Phase 1/2

Villejuif

2022-07-19

Active, closed

Study of INCB123667 in Subjects With Advanced Solid Tumors

NCT05238922Solid Tumors

DrugsRibociclib·Palbociclib·Olaparib·Fulvestrant

Incyte Corporation

Phase 1

291

Bordeaux, Lyon, Toulouse, Villejuif

2022-07-05

Recruiting

The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials

NCT05203172Solid Tumors

DrugsVemurafenib·Encorafenib·Binimetinib·Zirabev

Pfizer

Phase 4

210

Lille, Villejuif

2022-07-05

Active, closed

Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

NCT05364073Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer, HER2 Exon 20 Mutations

DrugFurmonertinib

ArriVent BioPharma, Inc.

Phase 1

160

Lyon, Toulouse, Villejuif

2022-06-30

Recruiting

Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

NCT05433142Clear Cell Renal Cell Carcinoma

Xencor, Inc.

Phase 1

307

Bourdeaux, Villejuif

2022-06-13

Recruiting

A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

NCT05384626Locally Advanced Solid Tumor, Metastatic Solid Tumor

DrugsNeladalkib·Repaglinide·Itraconazole·Midazolam

Nuvalent Inc.

Phase 1/2

840

Lyon, Nantes, Toulouse, Villejuif

2022-06-09

Recruiting

An Exploratory Study to Evaluate Immune Determinants of the Response to Adoptive Cell Therapy (ACT) in Solid and Hematologic Tumors

NCT05481502Solid Tumor, Adult, Solid Tumor, Childhood, Hematologic Cancer

Gustave Roussy, Cancer Campus, Grand Paris

Not applicable

160

Villejuif

2022-06-08

Recruiting

A Study of ASP3082 in Adults With Advanced Solid Tumors

NCT05382559Solid Tumor

DrugsSetidegrasib·Liposomal Irinotecan·Fluorouracil·Leucovorin

Astellas Pharma Inc

Phase 1

681

La Tronche, Bordeaux, Lyon, Villejuif

2022-06-08

Recruiting

Assessment of Cardiac Coherence Associated With Medical Hypnosis on Preoperative Anxiety in Oncological Surgery

NCT05197972Surgery, Oncology

Institut du Cancer de Montpellier - Val d'Aurelle

Not applicable

296

Montpellier, Lyon, Toulouse, Villejuif

2022-06-01

Active, closed

A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors

NCT05307705Breast Cancer

DrugsAnastrozole, Exemestane·Imlunestrant·Abemaciclib·Letrozole

Eli Lilly and Company

Phase 1

260

Lyon, Paris, Saint-Herblain, Strasbourg, Villejuif

2022-05-11

Active, closed

Evaluation of Salivary RNAs in the Presence of an Adnexal Mass of Ovarian Origin

NCT05514028Ovarian Cancer, Ovarian Cyst Benign, Borderline Ovarian Cancer

ZIWIG

Observational

746

Caen, Dijon, Bordeaux, Strasbourg, Toulouse, Saint-Grégoire, Le Kremlin-Bicêtre, Villejuif

2022-05-04

Active, closed

HDM201 and Pazopanib in Patients With P53 Wild-type Advanced/Metastatic Soft Tissue Sarcomas

NCT05180695Advanced Soft-tissue Sarcoma, Metastatic Soft-tissue Sarcoma

DrugsSiremadlin·Pazopanib

Centre Leon Berard

Phase 1/2

Bordeaux, Lyon, Marseille, Toulouse, Villejuif

2022-04-15

Recruiting

(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors

NCT05208047Advanced Gastrointestinal Stromal Tumors, Metastatic Cancer

DrugsBezuclastinib·Sunitinib·Midazolam

Cogent Biosciences, Inc.

Phase 3

482

Bordeaux, Lille, Lyon, Marseille, Rennes, Saint-Herblain, Toulouse, Villejuif

2022-04-14

Active, closed

Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant

NCT05317416Multiple Myeloma

DrugsElranatamab·Lenalidomide

Pfizer

Phase 3

854

Toulouse, Paris, Villejuif, Poitiers, Lille, Pierre-Bénite, Tours

2022-03-25

Active, closed

Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

NCT05477576GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors

DrugsRYZ101·Octreotide·Lanreotide·Sunitinib

RayzeBio, Inc.

Phase 3

343

Clichy, Lille, Montpellier, Nantes, Vandœuvre-lès-Nancy, Villejuif

2022-03-24

Recruiting

Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels

NCT05525338Drug Monitoring, Carcinoma, Non-Small-Cell Lung, Lung Cancer, Anaplastic Lymphoma Kinase Gene Mutation

DrugAlectinib

University Medical Center Groningen

Phase 4

196

Villejuif

2022-03-23

Active, closed

A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)

NCT05239728Carcinoma, Renal Cell

DrugsBelzutifan·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

1,800

Lyon, Strasbourg, Rennes, Chambray-lès-Tours, Besançon, Angers, Paris, Villejuif

2022-03-15

Active, closed

AGuIX Nanoparticles With Radiotherapy Plus Concomitant Temozolomide in the Treatment of Newly Diagnosed Glioblastoma

NCT04881032Glioblastoma

DrugTemozolomide

Centre Jean Perrin

Phase 1/2

Brest, Clermont-Ferrand, Grenoble, Lyon, Paris, Saint-Herblain, Strasbourg, Villejuif

2022-03-07

Recruiting

Study Evaluating the Safety and the Efficacy of Human T Lymphoid Progenitor (HTLP) Injection to Accelerate Immune Reconstitution After Umbilical Cord Blood (UCB) Transplantation in Adult Patients With Hematologic Malignancies (HTLP-ONCO)

NCT04707300Hematologic Malignancy

Assistance Publique - Hôpitaux de Paris

Phase 1/2

Paris, Pessac, Toulouse, Villejuif

2022-02-16

Recruiting

Selective Internal Radiation Therapy and Capecitabine (Chemotherapy) Treatment for Liver Cancer

NCT05265208Resectable Intrahepatic Cholangiocarcinoma

DrugCapecitabine

Center Eugene Marquis

Phase 2

Rennes, Pessac, Montpellier, Poitiers, Villejuif, Clichy, Créteil

2022-02-04

Active, closed

A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)

NCT05094336Advanced MTAP-null Solid Tumors

DrugsAnvumetostat·Docetaxel

Amgen

Phase 1/2

329

Dijon, Lille, Paris, Villejuif

2022-02-01

Recruiting

A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)

NCT05118789Locally Advanced Solid Tumor, Metastatic Solid Tumor

Nuvalent Inc.

Phase 1/2

359

Lyon, Nantes, Toulouse, Villejuif

2022-01-04

Active, closed

Lorlatinib Continuation Study

NCT05144997Non-Small-Cell Lung Cancer, NSCLC

DrugLorlatinib

Pfizer

Phase 4

Rennes, Villejuif

2021-12-28

Active, closed

Effectiveness of the SpaceOAR Vue System in Subjects With Prostate Cancer

NCT04905069Prostate Cancer

Boston Scientific Corporation

Not applicable

500

Villejuif, Levallois-Perret

2021-12-21

Active, closed

A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

NCT04819100Carcinoma, Non-Small-Cell Lung

DrugSelpercatinib

Eli Lilly and Company

Phase 3

152

Lyon, Marseille, Rouen, Le Plessis-Robinson, Villejuif, Paris

2021-12-20

Recruiting

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

NCT05216432PIK3CA Mutation, Solid Tumor, Adult, HER2-negative Breast Cancer, Breast Cancer

DrugsRLY-2608·Atirmociclib·Ribociclib·Palbociclib

Relay Therapeutics, Inc.

Phase 1

930

Lyon, Bordeaux, Villejuif

2021-12-08

Active, closed

Short-term Pre-OPerative Durvalumab (MEDI 4736) in Early Small Triple Negative Breast Cancer Patients (POP-Durva)

NCT05215106Early Small (cT1N0) Triple Negative Breast Cancer

DrugDurvalumab

Gustave Roussy, Cancer Campus, Grand Paris

Phase 2

200

Bordeaux, Lyon, Villejuif

2021-12-06

Active, closed

A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)

NCT05060016Relapsed/Refractory Small Cell Lung Cancer

DrugTarlatamab

Amgen

Phase 2

222

Marseille, Paris, Pierre-Bénite, Rennes, Strasbourg, Toulouse, Villejuif

2021-12-01

Active, closed

Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC

NCT05043090Papillary Renal Cell Carcinoma

DrugsSavolitinib·Sunitinib·Durvalumab

AstraZeneca

Phase 3

148

Bordeaux, Quimper, Toulouse, Villejuif

2021-10-28

Active, closed

A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations

NCT05048797Locally Advanced or Metastatic Non-Small Cell Lung Cancer

DrugsTrastuzumab deruxtecan·Pemetrexed·Cisplatin·Carboplatin

AstraZeneca

Phase 3

454

Bordeaux, Dijon, Le Mans, Lyon, Marseille, Nantes, Toulouse, Villejuif

2021-10-28

Recruiting

First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)

NCT05099172Advanced Non-small Cell Lung Cancer, EGFR Mutation, HER2 Mutation

Bayer

Phase 1/2

430

Lyon, Bordeaux, Nantes, Saint-Herblain, Marseille, Paris, Villejuif

2021-10-25

Active, closed

A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors

NCT04857372Mesothelioma

Novartis Pharmaceuticals

Phase 1

137

Villejuif

2021-10-21

Recruiting

Comparison of the Effectiveness of Two Psycho-physical Interventions: Mindfulness Based Relapse Prevention (MBRP) and Unguided Meditative Relaxation in Patients With Alcohol Use Disorder

NCT04598399Alcohol Use Disorder (AUD)

Centre Hospitalier Universitaire de Nīmes

Not applicable

168

Angers, Issy-les-Moulineaux, Nantes, Nîmes, Paris, Sèvres, Villejuif

2021-10-20

Active, closed

A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

NCT05104866Breast Cancer

DrugsEribulin·Dato-DXd·Vinorelbine·Capecitabine

AstraZeneca

Phase 3

732

Bezannes, Bordeaux, Lille, Lyon, Montpellier, Plérin, Toulouse, Villejuif

2021-10-18

Active, closed

Study of Vimseltinib for Tenosynovial Giant Cell Tumor

NCT05059262Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath, Tenosynovial Giant Cell Tumor, Diffuse

DrugVimseltinib

Deciphera Pharmaceuticals, LLC

Phase 3

123

Bordeaux, Lyon, Villejuif

2021-10-14

Active, closed

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab

NCT05029882Non-Small Cell Lung Cancer, Advanced Solid Tumors, Gastroesophageal Adenocarcinoma, Colorectal Cancer

DrugsTelisotuzumab Adizutecan·Trifluridine/Tipiracil·Bevacizumab

AbbVie

Phase 1

520

Bordeaux, Saint-Herblain, Nice, Lyon, Villejuif, Dijon, Paris

2021-10-13

Active, closed

A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors

NCT04931342Ovarian Cancer

DrugsCobimetinib·Ipatasertib·Giredestrant·Inavolisib

Hoffmann-La Roche

Phase 2

176

Besançon, Caen, Lyon, Paris, Rennes, Saint-Herblain, Toulouse, Villejuif

2021-10-07

Recruiting

Environment and Lung Cancer

NCT05119244Cannabis Use

Centre Chirurgical Marie Lannelongue

Not applicable

150

Le Plessis-Robinson, Paris, Villejuif

2021-10-01

Active, closed

A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer

NCT04931654Carcinoma, Non-Small-Cell Lung, Gastric Cancer, Gastroesophageal Junction Cancer

DrugSabestomig

AstraZeneca

Phase 1/2

136

Bordeaux, Rennes, Villejuif

2021-09-28

Active, closed

A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis

NCT05050136Primary Biliary Cholangitis, PBC

DrugVolixibat

Mirum Pharmaceuticals, Inc.

Phase 2

333

Grenoble, Lille, Nice, Paris, Strasbourg, Villejuif

2021-09-22

Recruiting

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

NCT04924075Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor, Von Hippel-Lindau Disease, Advanced Gastrointestinal Stromal Tumor

DrugBelzutifan

Merck Sharp & Dohme LLC

Phase 2

355

Strasbourg, Lyon, Marseille, Le Kremlin-Bicêtre, Paris, Villejuif

2021-08-12

Active, closed

Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM

NCT07217184Multiple Myeloma

DrugsBelantamab mafodotin·Isatuximab

GlaxoSmithKline

Phase 1/2

Villejuif

2021-07-29

Active, closed

Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

NCT04956640Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Endometrial Neoplasms, Ovarian Neoplasms

DrugsOlomorasib·Erbitux·Cetuximab·Pemetrexed

Eli Lilly and Company

Phase 1/2

540

Bordeaux, Lyon, Montpellier, Toulouse, Villejuif

2021-07-19

Active, closed

A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer

NCT04898634Prostatic Neoplasms

DrugPasritamig

Janssen Research & Development, LLC

Phase 1

216

Lyon, Marseille, Villejuif

2021-07-13

Recruiting

Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)

NCT04886804Neoplasm Metastasis, Non-Small Cell Lung Cancer

DrugZongertinib

Boehringer Ingelheim

Phase 1

554

Bron, Lyon, Marseille, Paris, Rennes, Villejuif

2021-07-02

Recruiting

Sequential Treatment With GEMBRAX and Then FOLFIRINOX Followed by Stereotactic MRI-guided Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

NCT04570943Locally Advanced Pancreatic Adenocarcinoma

Institut du Cancer de Montpellier - Val d'Aurelle

Phase 2

103

Marseille, Nîmes, Montpellier, Clichy, Dijon, Paris, Rennes, Villejuif

2021-06-16

Active, closed

177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer

NCT04689828Prostatic Neoplasms

DrugsARDT·Illuccix·Lu-PSMA

Novartis Pharmaceuticals

Phase 3

469

Angers, Bordeaux, Clermont-Ferrand, Lyon, Paris, Villejuif

2021-06-15

Recruiting

Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE)

NCT04498767Gynecologic Cancer, Skin Cancer, Head and Neck Cancer, Sarcoma

European Organisation for Research and Treatment of Cancer - EORTC

Not applicable

200

Lille, Villejuif

2021-06-10

Recruiting

PROADAPT-ovary/EWOC-2

NCT04284969Ovarian Cancer, Surgery

Hospices Civils de Lyon

Not applicable

292

Bordeaux, Chambéry, Dijon, Lyon, Pierre-Bénite, Pringy, Saint-Priest-en-Jarez, Villejuif

2021-06-03

Active, closed

A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread

NCT04810078Clear Cell Renal Cell Carcinoma

DrugsBMS-986298·Opdivo·Nivolumab

Bristol-Myers Squibb

Phase 3

681

Nice, Suresnes, Villejuif

2021-05-21

Active, closed

A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme

NCT04762069Glioblastoma Multiforme, Adult

DrugsCCNU·Lomustine

CNS Pharmaceuticals, Inc.

Phase 2

252

Lyon, Marseille, Montpellier, Paris, Saint-Herblain, Toulouse, Villejuif

2021-05-18

Active, closed

Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer

NCT04940325Metastatic Lung Cancer, Advanced Non Small Cell Lung Cancer, Unresectable Non-small Lung Cancer

DrugDato-DXd

Gustave Roussy, Cancer Campus, Grand Paris

Phase 2

100

Bordeaux, Brest, Caen, Créteil, Paris, Pierre-Bénite, Strasbourg, Villejuif

2021-05-12

Recruiting

Gustave Roussy Cancer Profiling

NCT04932525Solid Tumor, Unspecified, Adult

Gustave Roussy, Cancer Campus, Grand Paris

Not applicable

20,000

Villejuif, Le Plessis-Robinson, Paris, Suresnes

2021-05-10

Active, closed

Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)

NCT04862663Locally Advanced (Inoperable) or Metastatic Breast Cancer

DrugsCapivasertib·Ribociclib·Abemaciclib·Palbociclib

AstraZeneca

Phase 3

893

Bobigny, Limoges, Lyon, Plérin, Rouen, Saint-Herblain, Villejuif

2021-05-10

Recruiting

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

NCT04614103Metastatic Non Small Cell Lung Cancer

DrugLifileucel

Iovance Biotherapeutics, Inc.

Phase 2

170

Marseille, Nantes, Nice, Pierre-Bénite, Poitiers, Villejuif

2021-05-07

Active, closed

Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion

NCT04794699Solid Tumor

DrugsIDE397·Sacituzumab Govitecan

IDEAYA Biosciences

Phase 1

169

Bordeaux, Toulouse, Marseille, Dijon, Rennes, Villejuif

2021-04-14

Active, closed

A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)

NCT04817007Myelofibrosis

DrugsBMS-986158·Fedratinib·Ruxolitinib

Bristol-Myers Squibb

Phase 1/2

216

Brest, Marseille, Nice, Paris, Villejuif

2021-03-22

Recruiting

Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC

NCT04686305Locally Advanced or Metastatic Non-Small Cell Lung Cancer

DrugsVolrustomig·Rilvegostomig·Trastuzumab deruxtecan·Durvalumab

AstraZeneca

Phase 1

304

Bordeaux, Dijon, Pierre-Bénite, Saint-Herblain, Villejuif

2021-03-09

Active, closed

Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

NCT04699188KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal, Cancer of Lung

DrugsTNO155·Opnurasib·Tislelizumab

Novartis Pharmaceuticals

Phase 1/2

344

Lyon, Marseille, Villejuif

2021-02-24

Active, closed

HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

NCT04619004Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor

DrugPatritumab deruxtecan

Daiichi Sankyo

Phase 2

277

Toulouse, Nantes, Lyon, Brest, Grenoble, Paris, Rennes, Villejuif

2021-02-02

Recruiting

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

NCT04657068Advanced Cancer, Metastatic Cancer, Ovarian Cancer, Primary Peritoneal Cancer

DrugsIrinotecan·Gemcitabine

Artios Pharma Ltd

Phase 1/2

542

Villejuif, Paris, Poitiers, Bordeau, Marseille

2021-01-27

Recruiting

Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma

NCT04031677Retroperitoneal Sarcoma, Liposarcoma, Leiomyosarcoma

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3

250

Lyon, Montpellier, Paris, Strasbourg, Villejuif

2021-01-20

Active, closed

Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

NCT04589845Solid Tumors

DrugsCamonsertib·Belvarafenib·Pralsetinib·Divarasib

Hoffmann-La Roche

Phase 2

920

Bordeaux, Lille, Lyon, Marseille, Toulouse, Villejuif

2021-01-18

Recruiting

Health Effects of CArdiac FluoRoscopy and MOderN RadIotherapy in PediatriCs - Radiotherapy

NCT04746729Neoplasms

Institut National de la Santé Et de la Recherche Médicale, France

Observational

2,670

Caen, Villejuif

2021-01-11

Active, closed

A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1

NCT04534205Unresectable Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer

DrugPembrolizumab

BioNTech SE

Phase 2/3

358

Bordeaux, Caen, Dijon, Marseille, Paris, Tours, Villejuif

2021-01-07

Active, closed

A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations

NCT04639219Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast

DrugTrastuzumab deruxtecan

AstraZeneca

Phase 2

102

Bordeaux, Lyon, Villejuif

2020-12-30

Active, closed

Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours

NCT04735978Advanced Solid Tumor

DrugNivolumab

Replimune, Inc.

Phase 1

123

Villejuif

2020-12-29

Active, closed

A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer

NCT04538742Metastatic Breast Cancer

DrugsTucatinib·Pertuzumab·Trastuzumab deruxtecan·Durvalumab

AstraZeneca

Phase 1/2

245

Villejuif

2020-12-28

Active, closed

A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer

NCT04556773Metastatic Breast Cancer

DrugsCapivasertib·Anastrozole·Trastuzumab deruxtecan·Fulvestrant

AstraZeneca

Phase 1

138

Villejuif

2020-12-17

Recruiting

Study Evaluating Near-infrared Imaging Coupled With Indocyanine Green for Intraoperative Control of Resection Margins in ENT Surgery

NCT04842162Head and Neck Cancer

DrugIndocyanine Green

Gustave Roussy, Cancer Campus, Grand Paris

Phase 2

Villejuif

2020-12-15

Recruiting

A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab

NCT04590326Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Endometrial Cancer

DrugsUbamatamab·Sarilumab·Cemiplimab

Regeneron Pharmaceuticals

Phase 1/2

612

Pierre-Bénite, Dijon, Bordeaux, Caen, Villejuif

2020-12-08

Active, closed

Activity of Lorlatinib Based on ALK Resistance Mutations Detected on Blood in ALK Positive NSCLC Patients

NCT04127110Non Small Cell Lung Cancer

DrugLorlatinib

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2

Avignon, Bobigny, Brest, Créteil, Villejuif

2020-11-17

Active, closed

A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)

NCT04524871Advanced Liver Cancers

DrugsADG126·Tobemstomig·Tiragolumab·Tocilizumab

Hoffmann-La Roche

Phase 1/2

518

Dijon, Marseille, Rennes, Villejuif

2020-11-01

Active, closed

Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma

NCT04417621Melanoma

DrugsNaporafenib·Trametinib·Ribociclib

Novartis Pharmaceuticals

Phase 2

134

Lille, Marseille, Paris, Pierre-Bénite, Toulouse, Villejuif

2020-10-30

Recruiting

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

NCT04585750Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor

DrugsRezatapopt·Keytruda·Pembrolizumab

PMV Pharmaceuticals, Inc

Phase 1/2

300

Strasbourg, Bordeaux, Toulouse, Saint-Herblain, Clermont-Ferrand, Villejuif, Lyon, Nîmes

2020-10-29

Active, closed

Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC

NCT04550260Esophageal Squamous Cell Carcinoma

DrugsFluorouracil·Durvalumab·Capecitabine·Cisplatin

AstraZeneca

Phase 3

640

Besançon, Lille, Lyon, Montpellier, Reims, Rouen, Strasbourg, Villejuif

2020-10-19

Active, closed

Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

NCT04521686Cholangiocarcinoma, Chondrosarcoma, Glioma, Any Solid Tumor

DrugsLY3410738·Durvalumab·Gemcitabine·Cisplatin

Eli Lilly and Company

Phase 1

200

Bordeaux, Villejuif

2020-10-01

Active, closed

A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors

NCT05593094Advanced Solid Tumors, HER2-positive Breast Cancer

DrugZN-A-1041

Hoffmann-La Roche

Phase 1/2

210

Toulouse, Dijon, Lille, Lyon, Marseille, Saint-Herblain, Villejuif

2020-09-03

Active, closed

Efficacy and Safety of L19TNF in Previously Treated Patients with Advanced Stage or Metastatic Soft-tissue Sarcoma

NCT04733183Soft Tissue Sarcoma

DrugsOnfekafusp alfa·Dacarbazine

Philogen S.p.A.

Phase 2

Besançon, Bordeaux, Clermont-Ferrand, Lyon, Marseille, Montpellier, Toulouse, Villejuif

2020-08-28

Active, closed

A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma

NCT04522323Advanced Renal Cell Carcinoma

DrugsVolrustomig·Axitinib·Lenvatinib

MedImmune LLC

Phase 1

Villejuif

2020-08-05

Active, closed

Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib

NCT04421963Ovarian Cancer, Breast Cancer

DrugOlaparib

AstraZeneca

Phase 3

185

Lille, Lyon, Plérin, Villejuif

2020-08-04

Active, closed

Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies

NCT04561362Urinary Bladder Neoplasm, Triple Negative Breast Neoplasms, Hormone Receptor Positive, HER2-negative Neoplasms, Hormone Receptor Positive, HER2-low Neoplasms

DrugsZelenectide pevedotin·Keytruda·Pembrolizumab

BicycleTx Limited

Phase 1/2

329

Bordeaux, Lyon, Marseille, Rennes, Villejuif

2020-07-17

Recruiting

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

NCT04389632Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms, Esophageal Squamous Cell Carcinoma

DrugsSigvotatug vedotin·Keytruda·Cisplatin·Carboplatin

Seagen, a wholly owned subsidiary of Pfizer

Phase 1

1,006

Angers, Nice, Poitiers, Vandœuvre-lès-Nancy, Villejuif

2020-06-08

Active, closed

Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM

NCT07084896Multiple Myeloma

DrugsNirogacestat·Belantamab mafodotin

GlaxoSmithKline

Phase 1/2

106

Lille, Villejuif

2020-06-08

Recruiting

Securing Access to Innovative Molecules in Oncology and Hematology for Children, Adolescents and Young Adults

NCT04477681Pediatric Cancer

Gustave Roussy, Cancer Campus, Grand Paris

Observational

1,150

Villejuif, Amiens, Angers, Besançon, Bordeaux, Brest, Caen, Clermont-Ferrand

2020-04-09

Recruiting

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

NCT04094610Locally Advanced Solid Tumors, Metastatic Solid Tumors, Lymphoma, Primary CNS Tumors

DrugRepotrectinib

Turning Point Therapeutics, Inc.

Phase 1/2

Lyon, Angers, Bordeaux, Marseille, Nantes, Paris, Villejuif

2020-03-12

Active, closed

A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)

NCT04195750Carcinoma, Renal Cell

DrugsBelzutifan·Everolimus

Merck Sharp & Dohme LLC

Phase 3

755

Strasbourg, Bordeaux, Caen, Besançon, Nîmes, Vandœuvre-lès-Nancy, Pierre-Bénite, Villejuif

2020-02-27

Active, closed

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

NCT04262466Select Advanced Solid Tumors

DrugBrenetafusp

Immunocore Ltd

Phase 1/2

410

Bordeaux, Villejuif, Lyon, Paris

2020-02-25

Active, closed

DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer

NCT04042701Breast Cancer, Non-small Cell Lung Carcinoma

DrugsTrastuzumab deruxtecan·Keytruda·Pembrolizumab

Daiichi Sankyo

Phase 1

115

Bordeaux, Créteil, Marseille, Marsielle, Poitiers, Toulouse, Villejuif

2020-02-10

Active, closed

Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET

NCT03972488Gastro-enteropancreatic Neuroendocrine Tumor

DrugsOctreotide LAR·Lutathera

Advanced Accelerator Applications

Phase 3

226

Clichy, Lyon, Montpellier, Nantes, Villejuif

2020-01-08

Recruiting

A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis

NCT04176198Myelofibrosis

DrugsMomelotinib·Ruxolitinib

Sumitomo Pharma America, Inc.

Phase 1/2

240

Amiens, Angers, Lyon, Nice, Nîmes, Paris, Poitiers, Villejuif

2019-12-16

Active, closed

A Clinical Trial Evaluating TG4050 in Head and Neck Cancer

NCT04183166Squamous Cell Carcinoma of Head and Neck

Transgene

Phase 1/2

Bordeaux, Marseille, Paris, Toulouse, Villejuif

2019-12-12

Active, closed

CRESPI - Respiratory Health of Children in Daycare

NCT04170881Respiratory Health

Institut National de la Santé Et de la Recherche Médicale, France

Observational

2,000

Villejuif

2019-12-03

Active, closed

Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM

NCT07217119Multiple Myeloma

DrugsFeladilimab·Belantamab mafodotin

GlaxoSmithKline

Phase 1/2

Villejuif

2019-11-26

Recruiting

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

NCT04065399Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Lineage Acute Leukemia, Mixed Phenotype Acute Leukemia

DrugsCobicistat·Revumenib

Syndax Pharmaceuticals

Phase 1/2

447

Paris, Pessac, Pierre-Bénite, Villejuif

2019-11-05

Recruiting

High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)

NCT04221035High-Risk Neuroblastoma, Patient With Insufficient Response Chemoimmunotherapy

DrugsDinutuximab beta·Vindesine·Cyclophosphamid·Thiotepa

Gustave Roussy, Cancer Campus, Grand Paris

Phase 3

800

Villejuif, Amiens, Angers, Besançon, Bordeaux, Brest, Caen, Clermont-Ferrand

2019-11-05

Active, closed

Pediatric Long-Term Follow-up and Rollover Study

NCT03975829Diffuse Astrocytoma, Anaplastic Astrocytoma, Astrocytoma, Oligodendroglioma, Childhood

DrugsDabrafenib·Trametinib

Novartis Pharmaceuticals

Phase 4

163

Rennes, Brest, Marseille, Paris, Vandœuvre-lès-Nancy, Villejuif

2019-11-04

Active, closed

Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments

NCT04058756Advanced Solid Tumors

DrugSpartalizumab

Novartis Pharmaceuticals

Phase 1

120

Lille, Lyon, Marseille, Villejuif

2019-10-30

Active, closed

Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors

NCT03964727Metastatic Solid Tumor

DrugSacituzumab Govitecan

Gilead Sciences

Phase 2

227

Bordeaux, Dijon, Toulouse, Villejuif

2019-10-15

Active, closed

Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

NCT04126200Multiple Myeloma

DrugsFeladilimab·Nirogacestat·Belantamab mafodotin·Isatuximab

GlaxoSmithKline

Phase 1/2

208

Lille, Villejuif

2019-10-07

Active, closed

A Patient Registry of Patients With High-risk Neuroblastoma Being Treated With the Monoclonal Antibody Dinutuximab Beta

NCT04253015Neuroblastoma

RECORDATI GROUP

Observational

125

Lille, Marseille, Villejuif

2019-09-30

Recruiting

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

NCT04104776Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant

DrugsTulmimetostat·Enzalutamide

Novartis Pharmaceuticals

Phase 1/2

300

Bordeaux, Lille, Lyon, Nantes, Saint-Herblain, Strasbourg, Villejuif

2019-09-18

Active, closed

GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors

NCT04083599Malignant Solid Tumor, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Melanoma

DrugsGEN1042·Adrucil·Nab-paclitaxel·Pemetrexed

Genmab

Phase 1/2

350

Bordeaux, Nice, Villejuif

2019-09-17

Active, closed

COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC

NCT04068610Metastatic Microsatellite-stable Colorectal Cancer

DrugsOleclumab·Folfox·Durvalumab·Bevacizumab

MedImmune LLC

Phase 1/2

Nantes, Villejuif

2019-09-13

Active, closed

First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

NCT04067336Advanced Malignant Neoplasm, Acute Myeloid Leukemia, Mixed Lineage Leukemia, Mixed Lineage Acute Leukemia

DrugsZiftomenib·Itraconazole·Midazolam

Kura Oncology, Inc.

Phase 1/2

263

Lille, Nantes, Paris, Pessac, Pierre-Bénite, Villejuif

2019-09-12

Active, closed

Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET

NCT03993873Advanced Solid Tumor, Metastatic Solid Tumors, MET Gene Alterations

Turning Point Therapeutics, Inc.

Phase 1

La Tronche, Saint-Mandé, Villejuif, Lyon

2019-09-05

Active, closed

A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer

NCT04077463Carcinoma, Non-Small-Cell Lung

DrugsLazertinib·Amivantamab·Pemetrexed·Carboplatin

Janssen Research & Development, LLC

Phase 1

701

Bordeaux, Lyon, Marseille, Paris, Poitiers, Saint-Mandé, Villejuif

2019-09-04

Active, closed

Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

NCT04044768Synovial Sarcoma, Myxoid Liposarcoma

USWM CT, LLC

Phase 2

Lyon, Pessac, Villejuif

2019-08-13

Recruiting

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

NCT04068597Haematological Malignancy, Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma

DrugsIxazomib·Elranatamab·Teclistamab·Pomalidomide

CellCentric Ltd.

Phase 1/2

250

Bordeaux, Villejuif

2019-08-09

Recruiting

Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors

NCT04064359Solid Tumor

Oxford BioTherapeutics Ltd

Phase 1

200

Marseille, Paris, Rennes, Strasbourg, Villejuif

2019-07-25

Active, closed

My Personalized Breast Screening

NCT03672331Breast Screening

UNICANCER

Not applicable

53,142

Villejuif

2019-07-18

Active, closed

Postoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for Recurrence

NCT03443856Gastric and Esophagogastric Junction Adenocarcinoma

DrugNivolumab and Ipilimumab

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2

197

Lille, Lyon, Villejuif

2019-07-17

Active, closed

A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)

NCT04035486Non-Small Cell Lung Cancer

DrugsPemetrexed/Cisplatin·Pemetrexed/Carboplatin·Osimertinib

AstraZeneca

Phase 3

587

Bordeaux, Lyon, Montpellier, Villejuif

2019-07-02

Active, closed

Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC

NCT03997123Triple Negative Breast Neoplasms

DrugsCapivasertib·Paclitaxel

AstraZeneca

Phase 3

923

Brest, Lyon, Marseille, Montpellier, Nice, Paris, Saint-Herblain, Villejuif

2019-06-25

Active, closed

A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors

NCT03899792Medullary Thyroid Cancer, Infantile Myofibromatosis, Infantile Fibrosarcoma, Papillary Thyroid Cancer

DrugSelpercatinib

Eli Lilly and Company

Phase 1/2

Villejuif

2019-06-13

Recruiting

Trial of Acetylsalicylic Acid and Atorvastatin in Patients With Castrate-resistant Prostate Cancer

NCT03819101Prostate Cancer

DrugsAcetylsalicylic acid·Atorvastatin

Gustave Roussy, Cancer Campus, Grand Paris

Phase 3

1,210

Villejuif, Besançon, Cergy-Pontoise, Clermont-Ferrand, Fort de France, Guadeloupe, Mougins, Nice

2019-06-06

Active, closed

Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients

NCT03829462Metastatic Colorectal Cancer (mCRC)

DrugsRegorafenib·Irinotecan

Institut du Cancer de Montpellier - Val d'Aurelle

Phase 3

377

Nice, Caen, Rennes, Reims, Perpignan, Lyon, Villejuif, Montpellier

2019-03-28

Active, closed

Stereotactic Body Radiation Therapy (SBRT) Efficiency and Toxicity in Liver Cancer

NCT03408665Liver Cancer, Liver Metastases

Centre Oscar Lambret

Not applicable

280

Lille, Dechy, Montpellier, Sarcelles, Strasbourg, Vandœuvre-lès-Nancy, Villejuif

2019-03-13

Active, closed

Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation

NCT03833154Carcinoma, Non-Small-Cell Lung

DrugDurvalumab

AstraZeneca

Phase 3

724

Bron, Dijon, Lyon, Nantes, Pierre-Bénite, Toulouse, Villejuif

2019-03-06

Active, closed

A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study

NCT03768063Cancer

DrugsEmactuzumab·Rucaparib·Cobimetinib·Vemurafenib

Hoffmann-La Roche

Phase 3

1,000

Angers, Nice, Lille, Marseille, Villejuif

2019-02-28

Active, closed

Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL

NCT03836261Chronic Lymphocytic Leukemia

DrugsAcalabrutinib·Venclexta·Obinutuzumab·Venetoclax

Acerta Pharma BV

Phase 3

984

Montpellier, Paris, Rennes, Rouen, Toulouse, Villejuif

2019-02-25

Active, closed

Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors

NCT03821935Advanced Solid Tumors Cancer

DrugsLivmoniplimab·Budigalimab

AbbVie

Phase 1

364

Toulouse, Lyon, Villejuif, Clermont-Ferrand

2019-02-21

Active, closed

Nivolumab for Pediatric and Adult Relapsing/Refractory ALK+, for Evaluation of Response in Patients With Progressive Disease (Cohort 1) or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse (Cohort 2)

NCT03703050Relapsing/Refractory ALK+ Anaplastic Large Cell Lymphoma

DrugsOpdivo·Nivolumab

Gustave Roussy, Cancer Campus, Grand Paris

Phase 2

Paris, Villejuif, Bordeaux, Créteil, Lille, Lyon, Toulouse, Vandœuvre-lès-Nancy

2019-01-02

Active, closed

Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)

NCT03765918Head and Neck Neoplasms

DrugsPlatinol·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

714

Nice, Marseille, Toulouse, Villejuif, Avignon, Paris

2018-12-17

Active, closed

Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)

NCT03742895Advanced Solid Neoplasms

DrugOlaparib

Merck Sharp & Dohme LLC

Phase 2

329

Poitiers, Nice, Strasbourg, Dijon, Bordeaux, Villejuif

2018-12-12

Active, closed

Predictive Markers of Immune-related Adverse Events in Patients Treated With Immune Stimulatory Drugs

NCT03984318Cancer

Gustave Roussy, Cancer Campus, Grand Paris

Not applicable

1,240

Villejuif, Chevilly-Larue, Le Kremlin-Bicêtre, Le Plessis-Robinson

2018-12-12

Recruiting

A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets)

NCT03767075Advanced Solid Tumor

DrugsFutibatinib·Amivantamab·Atezolizumab

Vall d'Hebron Institute of Oncology

Phase 2

1,000

Villejuif

2018-12-10

Active, closed

Post-Authorization Long-Term Safety Study of LUTATHERA

NCT03691064Neuroendocrine Tumors

DrugLutathera

Advanced Accelerator Applications

Observational

1,014

Clichy, Lyon, Villejuif

2018-11-28

Active, closed

A Trial Evaluating the Addition of Nivolumab to Cisplatin-RT for Treatment of Cancers of the Head and Neck

NCT03576417Squamous Cell Carcinoma of Head and Neck

DrugsNivolumab·Cisplatin

Groupe Oncologie Radiotherapie Tete et Cou

Phase 3

680

Villejuif

2018-10-10

Active, closed

Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer

NCT03539536Non-small Cell Lung Cancer

DrugTelisotuzumab vedotin

AbbVie

Phase 2

270

Marseille, Bordeaux, Lille, Paris, Bron, Lyon, Créteil, Villejuif

2018-10-10

Recruiting

Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

NCT03715933Ewing Sarcoma, Colorectal Adenocarcinoma

DrugsINBRX-109·Temozolomide·Fluorouracil·Leucovorin

Inhibrx Biosciences, Inc

Phase 1

411

Lyon, Villejuif

2018-10-08

Recruiting

Low-level Laser Therapy in the Prevention of Chemotherapy-induced Mucositis in Children and Young Adults

NCT03983369Mucositis Oral

Gustave Roussy, Cancer Campus, Grand Paris

Phase 3

315

Villejuif, Lille, Paris, Rennes

2018-08-29

Cite this view

Priya Life Science (2026). Clinical trial register: studies with a French investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 2 November 2026. https://priyalifescience.com/clinical-trials-france/city/villejuif

Query this register directly

GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in France and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,731 studies in total at the last sync on 02 Nov 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 568 of those studies with a site in Villejuif.

How many clinical trials are recruiting in Villejuif?

309 of the 568 studies on this page are recruiting new participants as of the 02 Nov 2026, 03:18 UTC sync. A further 26 have not yet opened recruitment, 232 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Villejuif), 568 studies
Phase	Studies	Recruiting	Share
Phase 1/2	130	84	22.9%
Phase 3	130	57	22.9%
Phase 1	119	64	21%
Phase 2	105	51	18.5%
Not applicable	39	24	6.9%
Observational	27	20	4.8%
Phase 4	10	5	1.8%
Phase 2/3	8	4	1.4%

Most active sponsors

Lead sponsors with the most studies (Villejuif)
Lead sponsor	Studies	Recruiting
Gustave Roussy, Cancer Campus, Grand Paris	59	37
AstraZeneca	33	11
Merck Sharp & Dohme LLC	22	12
Bristol-Myers Squibb	21	13
GlaxoSmithKline	21	13
UNICANCER	19	12
Eli Lilly and Company	17	6
Novartis Pharmaceuticals	15	5
AbbVie	14	1
Assistance Publique - Hôpitaux de Paris	14	9

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.